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 Needle and syringe injection has been used for decades to successfully deliver 
vaccines and other biologics. Despite the widespread adoption of this delivery method it 
presents a number of difficulties for mass vaccinatio  campaigns in the developing 
world. Vaccine delivery using a needle and syringe increases the complexity and skill 
required to deliver vaccines, increases waste disposal costs due to sharps hazards and 
contributes to the high cost associated with cold chain storage and transport. A 
technology which could alleviate these issues could increase the reach and lower the cost 
of mass vaccination campaigns in the third world. A microneedle patch is a delivery 
vehicle that could meet this goal. Microneedles are micron-scale projections that can 
penetrate the skin and deliver proteins and other biologics in a targeted manner. They are 
simple to use, have the potential to reduce or eliminate the risk posed by contaminated 
sharps and could allow for the removal of some biologics from the cold chain. The goal 
of this project was to adapt exiting microneedle technologies to the currently approved 
live-attenuated measles and inactivated polio vaccines. This included stabilizing the 
vaccine components on both metal and dissolving microneedle patches. Following 
stabilization, the patches were used in-vivo to compare the immune response to 
traditional needle and syringe delivery. 
 The goal of the first project was to make the first a sessment of the feasibility of 
using the live-attenuated measles vaccine with metal microneedle patches. Since coating 
these patches requires the vaccine to be dried, initial studies focused on maintaining viral 
infectivity in this state. Stock vaccine rapidly lost activity after drying. This loss could be 
mitigated with the addition of excipients. The sugar trehalose proved to have potent 
stabilizing activity after both drying and storage at a range of temperatures. Vaccine dried 
and stored at 4oC and 25oC lost less than 1 log unit of activity after 30 days of drying. 
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Storage at higher temperatures resulted in a much higher level of infectivity loss. Using 
this formulation, metal microneedles were coated with a full human dose of measles 
vaccine using a dip-coating system. These patches were inserted into the skin of cotton 
rats and the immune response was compared to the sam  dose delivered intramuscularly. 
Neutralizing antibody titers between the two delivery routes were not statistically 
different. This showed that microneedle can be made which maintain measles vaccine 
activity, the antigen successfully reconstitutes in the skin after insertion and induces a 
potent antibody response. 
 The second study focused on enhancing the stability of he measles vaccine after 
drying and storage. This was done using a screen of excipients. The traditional assay 
typically used to measure measles virus activity is not well-suited to this task so an 
alternative assay was developed. Utilizing a genetically-modified measles vaccine virus 
which has been altered to express green fluorescent protein, a simple, quick and scalable 
test was designed which could rapidly measure the ti er of measles virus in-viro. Using 
this assay, more than 40 different excipients which have previously shown stabilizing 
activity in the literature were examined for their ability to minimize viral infectivity loss 
after drying and storage. It was discovered that the addition of a sugar and an amino acid 
resulted in a synergistic response. The combination of these two excipient types 
performed much better than either type individually. Using short-term screening studies 
at elevated temperatures it was found that a combinatio  of threonine and sucrose 
performed the best. This combination was tested to longer times to investigate its full 
stabilizing potential. After 6 months in storage at 4oC and 25oC, more than 90% of the 
original activity was maintained. Although storage at higher temperatures resulted in 
faster degradation, this formulation did show a stark improvement over the trehalose 
formulation used in the initial experiment. A full log unit of infectivity was not lost until 
more than 8 weeks of storage at 40oC using the stabilizers chosen in this screening study. 
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 The third study used the advances made to develop a dissolving microneedle 
patch which could deliver a full dose of measles vaccine into the skin. Dissolving needles 
had previously been used to deliver a variety of vaccines, but never a live-attenuated viral 
one. Initial experiments focused on optimizing the various steps required to successfully 
cast dissolving needle patches reliably and reproducibly. It was found that the stabilizing 
solution developed in the previous experiment was applicable to the needle casting 
process. After successful creation, dissolving microneedle patches encapsulating measles 
vaccine were inserted in the skin of rhesus macaques. The immune response to 
vaccination was compared to the same full human dose elivered subcutaneously using a 
syringe injection. The neutralizing antibody titers between the two groups were not 
statistically different. Furthermore, after a subcutaneous boost of monovalent measles 
vaccine all animals demonstrated an increase in titer. Dissolving microneedle patches 
were also stored at a range of temperatures to investigate their stability. Patches stored at 
4oC and 25oC showed no activity loss after 2 months of storage. Patches stored at 40oC 
did show up to 1 log unit of activity loss at the 2 month time point. 
 Finally, the knowledge gained from the measles experiments was adapted to 
creating dissolving microneedle patches which could deliver a full human dose of the 
inactivated polio vaccine. It was found that the same basic patch creation process could 
be used for IPV. Patches were created and assayed to nsure they contained the correct 
dose. These patches were inserted into the skin of rhesus macaques and the immune 
response was compared to a full dose delivered by intramuscular injection. Following 
low neutralizing titers among both groups after a single dose of IPV, a full dose boost 
was delivered using the same route. For polio serotypes 1 and 2 the neutralizing response 
was statistically the same. The response to serotype 3 was inferior in the microneedle 
patch group. It was determined that the assay used was not specific for the immunogenic 
region of IPV type 3. After testing with a refined assay it was found that the microneedle 
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patches only contained about 30% of a full dose. This is a possible explanation for the 
poor response seen to serotype 3. 
 These studies show that microneedles were safe, simple to use and can produce a 
potent immune response in multiple well-studied animal models. We believe that 
microneedles have the potential to overcome many hurdles that currently exist on the way 







CHAPTER 1  INTRODUCTION  
  
 The morbidity and mortality of measles and poliomyelitis has been greatly 
lessened due to the introduction of cheap and effective vaccines for each disease. 
Poliomyelitis is approaching complete global eradiction and endemic measles 
elimination is a standing goal for 4 of the 5 WHO regions [4, 5]. Both the live-attenuated 
measles vaccine and the inactivated polio vaccine are s fe and effective. They are, 
however, both delivered using a traditional needle and syringe. While this method of 
delivery is by far the most prevalent way to deliver accines, it does bring with it a 
number of drawbacks. 
 Syringe injection is a medical procedure which necessarily requires trained 
medical personnel. While this is not a massive burden in first world countries such as the 
United States, this can greatly diminish the reach of large-scale mass vaccination 
campaigns in the third world. Trained professionals are scarce in this region of the world 
and the requirement that they give each dose of vaccine increases the cost and decreases 
the throughput of these campaigns. Needles also repres nt a hazard following even a 
successful delivery. They must be properly disposed of to prevent both malicious and 
therapeutic reuse. If proper precautions are not taken, used needles can result in the 
spread of blood-borne diseases such as HIV and hepatitis [6]. Finally, syringe injection 
requires the transport and storage of both the vaccine and the delivery vehicle increasing 
bulk and taking up valuable storage space in the dev loping world. Both the measles and 
inactivated polio vaccines are sensitive to temperature fluctuations and therefore must be 
kept refrigerated during the entire transport process [7, 8]. This system of temperature-
controlled transport is known as the cold chain. Cold chain requirements vastly increase 
the financial and logistical challenges of large-scale vaccination campaigns. An 
integrated system which could maintain vaccine activity even after exposure to higher 
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temperatures could allow for house to house delivery. This technique has been used with 
the oral polio vaccine and has proven to be an effective way of maximizing vaccine 
coverage. 
 We believe that a new delivery system could solve many of the challenges 
presented by syringe injection of vaccines. A promising new development in this field 
has been the creation of microneedles. Microneedles ar  small, sub-millimeter sized 
needles which pierce the top layer of the skin and have the ability to deliver biologicals in 
a targeted manner [9-13]. This system is designed to eposit its payload in the upper 
dermal layers of the skin, rather than into the muscle or subcutaneous tissue. Previous 
work has shown that this method of antigen delivery is both safe and effective for a 
number of different vaccines. Different types of devic s within the field of microneedles 
have also been developed. Solid needles made out of silic n were the first to be designed 
[14]. A second generation made out of stainless steel w re created next. These metal 
patches were coated with the target vaccine which then re-dissolved into the skin after 
application. Many different biologics have been delivered to the skin using this 
microneedle design [1, 15-23]. While effective, this device did possess a slight biohazard 
sharps risk due to the fact that the needles, thoug small, remained on the patch after 
insertion. 
 Other microneedle systems have been created in which t e entire needle is made 
of a bio-absorbable polymer [2, 24-26]. These patches encapsulate the vaccine within the 
needle matrix which then dissolves after introduction nto the skin. After removal, the 
needles are no longer present on the patch which eliminates the risk of reuse and 
decreases the danger to both the patient and the administrator. Both types of microneedle 
patch were used during the course of this study. The final patch design was based on the 
dissolving needle concept primarily due to the increased safety profile following insertion 
and removal. 
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 To study microneedle delivery of both the live-attenuated measles and inactivated 
polio vaccines, this project covered four major areas: 
1. To design a microneedle system which can deliver th measles vaccine into the 
skin and then determine the immune response to vaccination in a small animal 
model. 
2. To perform an excipient screen to create a temperature-stable formulation of 
measles vaccine using a novel, high-throughput screen. 
3. To develop a dissolving microneedle patch which can maintain measles vaccine 
activity and then examine the immune response to skin-delivery in a non-human 
primate model. 
4. To develop a dissolving microneedle patch which can deliver the inactivated polio 
vaccine into the skin and then examine the response to vaccination in a non-
human primate model. 
This represents the first set of studies which examine vaccination against measles and 
polio using microneedles. It also examines the respon e of microneedle vaccination in 




CHAPTER 2  LITERATURE REVIEW 
 
2.1 Measles 
2.1.1 Virus and vaccine 
 
Despite the widespread availability of a cheap and effective vaccine, the measles 
virus remains one of the leading causes of vaccine-preventable morbidity and mortality in 
the world [27]. The measles virus is an enveloped, spherical, single-stranded RNA virus 
(Figure 1). It binds to cells using a hemmaglutinin receptor, which also mediates 
Figure 1: Measles virus structure [3]. 
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membrane fusion and viral entry into the target cell. Antibodies to this protein provide 
the strongest neutralizing response and can confer lifetime protection against the virus 
[28]. The measles virus is spread primarily through the air. It was originally thought that 
upon inhalation, the virus began to infect tissues lining the respiratory tract in the throat 
and lungs [29]. Recent work has shown this may not be the case. The discovery of nectin-
4 as a measles virus receptor, along with previously e tablished receptors SLAM (CD-
150) and CD-46 suggests an alternate pathway [30]. It is now thought that the virus first 
infects the myeloid and lymphatic tissues and then crosses into the respiratory epithelium 
in the later stages of infection [31]. This occurs through viral transmission from CD-150 
positive lymphocytes into respiratory epithelial cels using the nectin-4 receptor. This late 
stage infection is what ultimately results in a patient becoming contagious. Symptoms of 
a measles infection begin to show roughly 10 days after contact, presenting first with a 
fever and progressing 4 days later to a characteristic ash. Doctors who work in areas of 
high measles incidence can quickly diagnose the disase once the rash presents. In areas 
where measles transmission has been interrupted, th disease is sometimes misdiagnosed 
because of the relative ambiguity of the initial symptoms [32]. Treatment for a measles 
infection is mostly palliative, though some antiviral compounds such as ribavirin and 
interferon alpha have been used in cases of severe m asles [33]. The sole preventative 
measure is vaccination, which is over 90% effective when the recommended dose is 
delivered [34]. As with many vaccine-preventable diseases, high levels of herd immunity 
are important for interruption of transmission. The m asles virus is extremely infectious 
and can successfully spread in a population with a herd immunity of more than 95% [35]. 




2.1.2 Measles elimination efforts 
 
 The World Health Organization (WHO) has a standing goal of eliminating 
endemic measles through the use of mass vaccination campaigns [36]. In 2003, the 
organization set a goal of reducing measles mortality by 50% from 1999 levels. In that 
year, more than 850,000 people worldwide died of the disease [37]. Following a 
concerted effort to increase vaccination coverage in developing countries, measles deaths 
fell to approximately 164,000 worldwide by 2008 [38]. Further reductions in morbidity 
and mortality have been less successful. Despite a goal of complete endemic measles 
elimination in Europe by 2010, infections have actully been on the rise in the region. 
This is thought to be a result of decreased vaccinatio  coverage among school-age 
children [39]. Fears about the measles, mumps, and rubella (MMR) combination vaccine 
have circulated in the press and in a small number of peer reviewed journals [40]. A 
proposed link to autism has since been widely discredited and the original article making 
this claim has since been retracted by the journal [41]. Nevertheless, vaccination rates in 
developed countries such as the United State have fallen to the point that during the first 
19 weeks of 2011, there have already been more measles cases than any year since 1996 
[42]. Besides negative publicity, there are a number of factors associated with mass 
vaccination against measles which need to be addressed. Foremost is the requirement of 
the cold chain for proper vaccine storage. The live-att nuated measles vaccine rapidly 
loses activity after reconstitution from a lyophilized cake. Multi-dose vials must be fully 
used within 2 hours or they have to be discarded [43]. This time can be even shorter in 
regions where ambient temperatures can routinely top 40oC. A key link in the cold chain 
is the final trip away from major population centers into surrounding town and villages 
[44]. If the vaccine could be made stable for this period of time, a significant amount of 
vaccine which would otherwise be disposed of could be properly utilized. 
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2.1.3 Alternative delivery strategies for measles vaccine 
 
 Due to the issues presented by syringe injection, other avenues for delivery of the 
live-attenuated measles vaccine have been attempted. D livery into the skin was 
attempted using a variety of methods. The first attempt utilized a jet injector and 
attempted to deliver the same dose (1000 TCID50) both intradermally and subcutaneously 
[45]. This experiment found that both delivery methods produced similar results. No dose 
sparing was seen but all vaccinated children produce  potent antibody titers following 
measles vaccine administration. Other studies utilizing jet injection produced different 
results. A study in Zaire which attempted to deliver a 1/5 human dose intradermally 
found lower levels of both antibody production and seroconversion when compared to a 
full dose delivered subcutaneously using a needle and syringe [46]. The inferior response 
to low-dose measles vaccine delivered intradermally using a jet injector has been shown 
in other studies as well [47]. Other investigators have attempted to induce an immune 
response with even lower doses of measles vaccine. Transcutaneous delivery was 
attempted with negative results [48]. Here, skin on the arm was tape stripped and a 1/5 
dose was applied to the skin surface. The area was occluded with sterile gauze for 24 
hours. The exact dose that entered the skin was not determined. Following vaccination, 
the transcutaneous group did not produce neutralizing antibodies to measles. Further 
studies utilizing an extremely low-dose of measles vaccine delivered using a needle roller 
or bifurcated needle also showed insufficient neutralizing titers after delivery [49]. 
Finally, aerosol delivery of measles vaccine has been recently attempted in the rhesus 
macaque animal model. The investigators showed that delivery to the lungs was well 
tolerated and produced a potent humoral and cellular response [50]. This study did 
however utilize a dose 5x greater than the standard human dose. Studies have not been 
done comparing similar doses delivered by aerosol device versus a subcutaneous 
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injection. To date, no previous work has been done examining measles vaccine delivered 
using a microneedle patch. 
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2.2 Poliomyelitis 
2.2.1 Virus and vaccine 
 
 Unlike the measles virus, poliovirus was not a massive killer throughout human 
history. The fear of polio resided not in a fear of death, but in the images of children who 
had been crippled as a direct effect of infection. The vast majority of sufferers of polio 
recover completely, but in a small percentage of cases the virus enters the nervous system 
[51]. This can lead to permanent paralysis of limbs, and in extreme cases, paralysis of the 
respiratory system as well. Poliovirus is a small member of the enterovirus family which 
is known to follow the fecal-oral route of transmission [52]. The initial susceptible cells 
in a poliovirus infection are not currently known, but virus has been recovered in the gut-
associated lymph tissues including the tonsils, Peyer’s patch and feces prior to the onset 
of symptoms [52]. This indicates a latency period when the individual is infectious but 
displays none of the common outward symptoms of the dis ase. In the vast majority of 
infected individuals (95%) the disease progresses asymptomatically [53]. This makes 
diagnosis virtually impossible until a more serious case develops. The remaining 5% of 
infections proceed in a similar manner to many gastrointestinal illnesses. Common 
symptoms include sore throat, fever, diarrhea, headache and a general lack of energy. 
Diagnosis of polio infection can be confirmed via re l-time PCR of an individual’s stool. 
In a minute portion of infected individuals, the virus invades the central nervous system 
[54]. This can lead to the disease’s most well-know complication, paralytic 
poliomyelitis. This results in flaccid paralysis of the infected region, which can be fatal 
depending on the location and degree of paralysis. 
 Two different but similarly effective vaccines currently exist for the prevention of 
polio infection. A live-attenuated vaccine developed in the 1960’s by Albert Sabin 
rapidly became the predominant vaccine worldwide [55]. This was because of its simple 
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administration and inexpensive cost to produce. Thevaccine is given orally where the 
attenuated virus can infect the lymph tissues of the gut. This mimics the natural route of 
infection and creates potent intestinal immunity to subsequent infection [56]. Following 
vaccination, individuals excrete the attenuated vaccine strain for a number of days. This 
provides for secondary vaccination opportunities from a single immunized individual 
[55]. These reasons led to the selection of the oral polio vaccine (OPV) as the leading 
candidate for use in mass vaccination campaigns. A econd vaccine based on formalin 
inactivation of wild-type polio vaccine was developed by Jonas Salk during the same 
time period. This vaccine is given using an intramuscular injection and current 
formulations require multiple doses to achieve potent s roconversion [57]. Even though it 
was the first polio vaccine created, it was not used in large quantities until large areas of 
the world were certified polio-free. Along with the drawbacks associated with syringe 
injection, this vaccine also costs much more to produce than OPV [58]. 
 
2.2.2 Polio eradication efforts 
 
 The Global Polio Eradication Initiative was established by the World Health 
Organization in 1989 [5]. It initially called for zero incidence of worldwide polio cases 
by the year 2000. Progress towards this goal proceeded rapidly during the initial ramp up 
in global mass vaccinations. Following the delivery of millions of oral polio vaccine 
administrations, polio transmission was interrupted in the Americas with the last endemic 
case occurring in Peru in 1991 [59]. Despite some setbacks, numerous milestones have 
been achieved on the road to eradication of polio. For the first time in recorded human 
history, India has seen no new cases of polio over a 27 month period. Additionally, wild 
polio serotype 2 is thought to have been completed ra icated with no new cases detected 
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in over 2 years. As global eradication draws closer, a shift must occur in the polio vaccine 
used worldwide. 
 In a very small portion of individuals who receive OPV, viral recombination 
occurs, which can result in the attenuated strain reverting to the wild type virus [60]. This 
disease is known as vaccine-derived poliomyelitis. The risk of reintroducing endemic 
polio to the Americas via OPV led to a phase-out which culminated in 2000 with the 
elimination of the oral polio vaccine from the childhood immunization schedule [61]. 
Replacing it was a vaccine developed by Jonas Salk in the 1950’s which consists of wild-
type poliovirus that has been inactivated using formalin. This vaccine is given via a 
traditional syringe injection and does not confer the intestinal immunity provided by the 
oral vaccine. Because no live virus existed in the vaccine it also does not carry with it the 
risk of vaccine-derived poliomyelitis. The switch to the inactivated polio vaccine (IPV) is 
planned to occur worldwide following the complete interruption of endemic polio [61]. 
This brings with it a host of new complications. 
 Unlike OPV, IPV is delivered using a traditional needle and syringe [62]. This 
presents many problems for a mass vaccination setting. Injections require trained 
personnel to deliver the dose to prevent improper administration. This could vastly 
increase the cost of delivering IPV on a large scale by increasing the cost of campaign 
personnel. It could also slow throughput and reach of a vaccination campaign. While 
administration of OPV can be done on a door to door basis, IPV requires trained medical 
personnel to ensure proper storage of the vaccine and elimination of the medical sharps 
waste created after delivery. Medical waste and the saf  disposal of sharps presents a 
problem for large-scale vaccination campaigns [63]. This burden is in addition to the 
increased risk of needle reuse or misuse created by delivery using syringe injection. An 
alternative delivery system for IPV which could mitigate many of these issues be 
beneficial to the continued campaign to eradicate polio worldwide. 
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2.2.3 Alternative IPV delivery methods 
 
 Due to the rapid rise in use of OPV, alternative mthods of delivering IPV have 
not been well studied until more recently. The original examination of IPV intradermal 
delivery was performed by Jonas Salk using a jet inj ction system [64]. He found that a 
fractional (1/6, 1/10) dose delivered using this method produced an inferior immune 
response when compared to a full dose delivered intramuscularly. Jet injection of 
fractional IPV was not examined again until more recently. A study in Oman found that a 
fractional (1/5) dose of IPV induced similar seroconversion rates to IPV type 1 and type 3 
when compared to traditional subcutaneous injection [65]. The study did, however, show 
significantly lower antibody titers following ID administration. This phenomena was also 
seen in a study performed in Cuba. The investigators f und that a fractional (1/5) dose 
delivered using a jet injector produced both inferior antibody titers and lower 
seroconversion rates [66]. These results show that there still exists a need for a cheap, 
effective, and simple method of delivering IPV which an induce a comparable immune 
response to syringe injection. 
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2.3 Vaccine delivery 
2.3.1 Intradermal delivery 
 
 The vast majority of vaccines are currently delivered to muscle or subcutaneous 
regions of the skin. This is due primarily to ease of access to the location and the 
simplicity required administering injections to these regions [67]. In recent years, more 
and more research has concentrated on evaluating other areas of the skin as possible 
candidates for a more effective vaccine delivery location. The skin has become an active 
area of interest because of its immunological makeup. Owing to its barrier function for 
the body, the dermal and epidermal layers of the skin contain numerous resident dendritic 
cells [68]. These cells function as an immune surveillance system, sampling the 
extracellular environment and trafficking foreign sub tances to the draining lymph nodes. 
Here portions of the offending proteins are presented to immune effector cells which 
begin the process of the adaptive immune response. I  addition, these cells secrete 
cytokines which can help ramp up the innate immune system, which is the body’s first 
defense against foreign pathogens. These cells, along with macrophages, invade the 
muscle tissue after an injury such as a syringe injction. However, in the skin, they 
already exist, waiting for an activating interaction. It is thought that delivering vaccine 
antigens directly into the intradermal layer of the skin may result in a more rapid and 
more potent immune response [69]. This could serve to provide dose-sparing activity or 
might be beneficial in overcoming the maternal antibod es which can prevent 
seroconversion in young infants [70]. Both of these benefits would be useful in a third 
world setting. 
 Historically the most well-known example of an intradermal vaccine was the 
smallpox vaccine. This was traditionally delivered to the skin via a small, two-pronged 
device known as a bifurcated needle. A very small amount of liquid vaccine was trapped 
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between the prongs using simple surface tension. The device was then repeatedly inserted 
into the skin, delivering the payload [71]. This proved to be a relatively inefficient and 
unreliable method of delivery. This problem was mitiga ed to some extent with the 
creation of jet injectors. A jet injector is a device which aerosolizes a liquid vaccine and 
then rapidly propels that mist across the barrier layers of the skin [72]. By altering the 
nozzle dimensions, these devices can direct their payload to the intradermal region. The 
velocity required to reliably penetrate the outer layer of the skin did create some 
drawbacks. It was found that a small quantity of biological material could be propelled 
back into the jet injector, creating an avenue for cross contamination between patients 
[73-75]. This led to a sharp drop in their use in mass vaccination campaigns in the 
1990’s. Another popular method for administering substances to the intradermal layer of 
the skin is known as the Mantoux method [76]. This is widely used in the tuberculin (TB) 
skin test. In this procedure a high-gage needle is inserted into the skin at a very small 
angle. The contents are then deposited into the skin forming a distinctive “bleb”. This 
procedure requires substantial training to confer expertise [11]. In addition, the dose is 
delivered across many layers of skin because of the large size of the needle bore 
compared to the relative thickness of the skin. A promising technology which overcomes 




 Microneedles are micron-sized needles made of stainless steel or a variety of 
polymers which have the ability to penetrate the barrier layers of the skin [13]. The basic 
premise of microneedle-mediated drug delivery is baed on the fact that the barrier layer 
of the skin only comprises the upper most layers of the skin. This region is roughly 20 
microns thick [77]. Studies have shown that once this layer has been breached, drug 
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delivery into the skin increases by orders of magnitude [10]. This makes it unnecessary to 
penetrate deeply into the skin to efficiently delivr a payload. A depth of between 100 
µm and 1 mm is the ideal location for the distribution of drugs targeted to the intradermal 
layer of the skin. Microneedles patches have been cr ated out of both metal and 
dissolvable polymer. 
 
2.3.2.1 Solid, metal microneedles 
 
 A number of different drugs and antigens have been successfully delivered via 
microneedle systems. An early system composed of solid, silicon needles created by 
adapting common microelectronics processes showed that after insertion of the needle 
array the permeability of the skin increased by four rders of magnitude to the small 
Figure 2: Metal microneedles at high magnification [1].A: Metal microneedle patch 
compared to a traditional hypodermic needle. B-i: Single metal microneedle coated 
with a vaccine solution. B-ii: Single metal microneedle after successful insertion into 
the skin.
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molecule calcein [10]. Subsequent research confirmed this result with larger molecules 
such as human growth hormone and bovine serum albumin [25, 78, 79]. This work led to 
the idea of skin vaccination using the microneedle system. 
 Vaccines typically consist of either whole virus particles or selective antigenic 
proteins. These molecules or supramolecular assembli s are much too large to passively 
diffuse through the skin, so the microneedle system s emed like a logical vector for 
delivery. It was shown that after coating the inactivated influenza vaccine on the surface 
of a metal needle array, mice could be immunized by simply inserting the needles into 
bare skin [80]. After vaccination it was shown that the groups receiving the microneedle 
patch had superior protection against a subsequent challenge with live influenza virus. 
Following challenge, microneedle group mice had lower levels of lung viral titer when 
compared with mice receiving the same dose via a trditional intramuscular injection [1]. 
It is theorized that this improved response is due in part to increased levels of immune 
system cells secreted IFN-y and IL-4, two key mediators of both the innate and adaptive 
immune responses [1]. This supports the theory that t e skin is a potent reservoir of 
primed immune surveillance cells and a superior target for vaccine delivery. Further 
studies examined the ability of microneedles to confer dose-sparing. 
 Microneedle delivery of an influenza virus-like particle vaccine showed superior 
protective ability at lower antigen doses compared to the same vaccine delivered via 
intramuscular injection. At 1/3 of the full antigen dose, the microneedle groups had full 
protection against a lethal challenge while the intramuscular group had only 40% of the 
animal survive the challenge [21]. Other vaccines have also been successfully delivered 
using solid, metal microneedles such as hepatitis C and Bacillus anthracis [17, 81-83]. 
Further development of the microneedle technology itself has been undertaken. 
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2.3.2.2 Dissolving microneedles 
 
 
 Polymer needles have been created which have the ability to encapsulate various 
antigens and disperse them once they have entered the skin. These needles have been 
made with a variety of polymers such as polylactic-o-glycolic acid (PLGA), 
polyvinylpyrrolidone (PVP) and maltose [2, 26, 84]. Each of these polymers has unique 
characteristics including dissolution time, strength and the ability to impact the stability 
of the encapsulated antigen. Polymer needles have som  features which make them an 
ideal candidate for vaccination campaigns in the third world. Following delivery of the 
payload into the skin, the needle patch is rendered harmless by the dissolution of the 
polymer needles. Unlike stainless steel needles, after use a polymer-based needle system 
has none of the dangers commonly associated with sharp . The patches are water soluble 
and can be easily and cheaply disposed.  
 Dissolving microneedles have also been previously ed to successfully deliver 
vaccines [22, 85-87]. In one study influenza vaccine was encapsulated in a PVP 
microneedle patch and subsequently deposited into the skin [2]. This produced a robust 
Figure 3: Dissolving microneedle patches before and after insertion [2]. 
A: Dissolving microneedle patch at high magnification. B: Pig skin after insertion 
and dissolution of a microneedle patch containing adye. C: Dissolving microneedle 
patch compared to a US nickel coin. D: Dissolving microneedle patch before and 
after insertion. 
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immune response that fully protected mice against a lethal challenge. It was found that 
the microneedle patch induced a more potent cellular immune response that resulted in 
decreased lung viral titers following challenge. Various geometries and needle designs 
have also been investigated. A dissolving needle with an arrowhead designed was created 
to facility rapid delivery of the microneedle into he skin [84]. This unique geometry 
allowed for nearly complete microneedle delivery in seconds. Rapid needle deposition in 
the skin combined with a slow-dissolving polymeric needle has the potential to achieve 
controlled release-style kinetics. 
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2.4 Vaccine Stability 
2.4.1 Vaccine wastage 
 
 Product wastage presents a major problem during mass-v ccination campaigns. It 
is estimated that up to 44% of the deliverable vaccine does not make it to a patient due to 
spoilage caused by temperature fluctuations or improper handling [88]. This loss adds to 
the cost of the campaign and lowers the eventual number of doses delivered. The current 
attempts to prevent vaccine spoilage revolve primarily round maintenance of the cold 
chain and increasing stability during storage. Virtually all currently licensed vaccines 
have a recommended storage temperature of under 8oC [89]. This becomes increasingly 
expensive as the vaccine is moved from first to third world countries. Transport, shipping 
and storage at the site of vaccination constitutes a major portion of the cost to deliver 
vaccines on a mass-scale [44]. Minimizing the need for low-temperature storage could 
greatly reduce this cost. However, simply increasing the stability at an elevated 
temperature for a transient period of time could lessen vaccine spoilage during the crucial 
period when the vaccine moves from the city center out into the community for delivery. 
 
2.4.2 Measles vaccine stability 
 
 Since the product consists of an intact, infectious virus, the stabilization of the 
measles vaccine has challenges not present with inactivated or subunit vaccines. 
Maintaining both the stability of the viral unit aswell as the encapsulated RNA is crucial 
to retaining infectivity [90]. Significant work has been done in an attempt to solve this 
complex problem. Technology such as lyophilization and the addition of excipients to the 
final vaccine solution prior to packaging have been crucial in getting the stability of the 
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vaccine to its current state [91]. Further work focused independently on the two crucial 
times when vaccine wastage can occur. 
 First, measles infectivity during storage has been xamined by a number of 
groups. The method by which the vaccine is dried before storage has been a crucial area 
of research. Spray drying has been shown to create a dry cake which retains significant 
infectivity after storage at elevated temperatures [92]. The researchers showed that while 
standard lyophilized measles vaccine lost 1 log(TCID50) after only a week at 37°C, their 
spray dried formulation did not lose this amount until 8 weeks of storage. It was 
hypothesized by the authors that spray-drying result d in a lower final water content 
resulting in a more stable dry preparation. This work also identified a number of possible 
stabilizing excipients such as human serum albumin, various amino acids and cations. 
Other groups have examined drying using a novel process called CAN-BD which utilizes 
super-critical CO2 to remove water content [93]. When this process wa applied to 
measles vaccine it was shown to maintain significant stability after 1 week at 37oC [94]. 
It was also found the type of sugar added to the vaccine solution prior to processing had 
the potential to alter both the final water content a d eventual stability after storage.  
 Work has also been done to enhance the stability of he measles vaccine after 
reconstitution. The WHO currently recommends that measles vaccine must be delivered 
within 2 hours of reconstitution to ensure the proper dose is delivered [43]. This can 
result in vaccine wastage since the 10-dose vial is widely used during measles 
vaccination campaigns [95]. A major advance in the ability to rapidly screen measles 
formulation was the development of a measles vaccine virus which contained the genetic 
material for green fluorescent protein (eGFP-MeV) [96, 97]. Using this novel virus, 
investigators were able to rapidly screen a large number (>11,000) of compounds to 
assess their ability to minimize the loss in reconstituted measles vaccine [98]. They, like 
other researchers, found that a combination of sugar , mino acids and buffering 
components could greatly decrease infectivity loss at elevated temperatures. Their best 
 21
liquid formulation was able to withstand 8 hours at 40oC with less than 1 log(TCID50) 
loss in infectivity. 
 While promising, all of these efforts fall short of developing a measles vaccine 
preparation that completely mitigates infectivity loss at elevated temperatures. Further 
work is required to both increase the stability of the measles vaccine and to optimize 
transport and storage to the point where product wastage is no longer a pervasive 
problem. 
 
2.5 Motivations for Research 
 
 Despite efforts to simplify delivery of the measles and polio vaccines, hurdles still 
exist. The injectable delivery systems currently used to administer both of these vaccines 
increase the cost of campaigns through a number of ways. The requirement for trained 
medical personnel limits the reach of large-scale campaigns while also lowering the 
speed at which doses can be delivered. The sharps waste created by the used needles is a 
significant burden that increases the cost and logistical complexity of vaccine campaigns. 
Finally, errors in reconstitution, delivery and vaccine storage result in the loss of a 
significant quantity of vaccine stock. Microneedles are a new delivery platform that has 
the potential to alleviate many of these concerns. Adapting the measles and inactivated 
polio vaccine for skin delivery using microneedles would represent a significant advance, 
removing many of the hurdles remaining in the eradic tion of both of these diseases. 
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CHAPTER 3  SPECIFIC AIMS AND HYPOTHESES 
 
Aim 1: Determine the immune response to skin-vaccination of measles in a small 
animal model. The live-attenuated measles vaccine can be adapted to existing 
microneedle patch systems and delivered to the skin of a cotton rat. We hypothesize that 
vaccination will result in a potent immune response comparable to a traditional 
injection. The goal of this aim was to create a microneedle patch that had the ability to 
deliver a full human dose of the measles vaccine to the skin of a small animal. These 
patches were then used to vaccinate cotton rats. 
  
Aim 2:  Enhance stability of dried live-attenuated measles vaccine using an excipient 
screen. We hypothesize that using a high-throughput infectivity screen, the stability of 
measles virus after drying can be significantly enhanced by the addition of excipients. 
This aim focused on the creation of a simple, high-throughput assay to quickly asses the 
stabilizing potential of a number of pharmaceutical excipients. This assay resulted in the 
discovery that the amino acid threonine and the sugar sucrose, in combination, could 
mitigate loss after drying and storage for 6 months at room temperature.  
  
Aim 3:  Determine the immune response in the rhesus macaque to measles 
vaccination using a microneedle patch. We hypothesize that delivery of measles vaccine 
to the skin using a dissolving microneedle patch will produce a potent immune response 
in the rhesus macaque. The rhesus macaque is a commonly used model for testing of 
measles vaccines. It is often used as a key predictor of the immune response to 
vaccination in humans. Here, dissolving microneedle patches were created that contained 




Aim 4:  Determine the immune response in the rhesus macaque to inactivated polio 
vaccination using a microneedle patch. We hypothesize that delivery of IPV to the skin 
using a dissolving microneedle patch will produce a potent immune response in the 
rhesus macaque. The rhesus macaque is a commonly used model for testing polio 
vaccines. Here, dissolving microneedle patches were created that contained a full human 
dose of the inactivated polio vaccine. These patches were used to deliver IPV to the skin 
of rhesus macaques.  
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CHAPTER 4  Measles Vaccination in cotton rats using a 
Microneedle Patch  
         
4.1 Introduction 
 
Despite the widespread availability of an inexpensive and effective vaccine,  
measles virus is one of the leading causes of vaccine-preventable morbidity and mortality 
among children worldwide [27]. High levels of coverage are necessary for interruption of 
measles transmission. Measles vaccination programs h ve dramatically reduced the 
incidence of disease in both developed and developing countries [4, 99]. More than 4.5 
million measles deaths have been prevented as of 2008 through implementation of the 
vaccination strategies developed by WHO and UNICEF. Global mortality has declined 
by 74% from an estimated 733,000 deaths in 2000 to 139,300 in 2010 [100]. Measles 
elimination, defined as the absence of endemic transmission of virus, has been achieved 
and sustained in the WHO Region of the Americas since 2002, and four of the five other 
WHO regions, European, Eastern Mediterranean and Western Pacific, have targeted 
measles for elimination by 2020 or earlier [101].  
The measles vaccine is currently delivered by subcutaneous injection using a 
needle and syringe. This delivery method creates th requirement for specifically trained 
healthcare personnel to administer each vaccine dos, typically at centralized locations. 
In contrast, the global campaign to eradicate polio has been possible, in part, because of 
the simplicity of delivering the oral polio vaccine, which can be administered by 
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minimally trained personnel. Decreasing the logistical challenges associated with 
delivery of measles vaccine could increase vaccinatio  coverage and reduce vaccination 
campaign costs.  
Hypodermic injections create hazardous medical waste which must be safely 
destroyed. Preventing needle theft and reuse throug responsible disposal methods adds 
significant costs to vaccination campaigns. For example, a relatively small measles 
vaccination campaign in the Philippines generated over 130,000 kg of sharps waste [102]. 
Another logistical challenge with the standard vaccination scheme is the requirement of a 
cold chain for vaccine storage and transport. After reconstitution, multi-dose vials must 
be used within 2 h or discarded [43]. This leads to vaccine wastage and increased 
program costs. A delivery system that eliminates the need for reconstitution and reduces 
or eliminates the need for cold storage and transport could enable more efficient use of 
measles vaccine and decrease the cost per delivered dos . 
Measles vaccination using a microneedle patch may be able to address some of 
the limitations of conventional hypodermic injection and thereby facilitate measles 
mortality reduction and elimination programs. Microneedles are micron-sized needles 
made of metal or polymer that are designed to achieve the efficacy of hypodermic 
injection with the simplicity of a patch [12, 103]. Microneedles offer the possibility of 
eliminating or mitigating many of the logistical challenges associated with the current 
vaccination strategy, including reduced cost, simplified transport and storage, and 
increased safety. The microneedles used in this study remain on the patch after it is 
removed and could present a small risk for disease transmission as a sharps hazard. 
However, microneedles can also be fabricated from dissolving polymers in which case no 
 26
potentially infectious, sharps waste would be generated [2, 66]. Microneedles require a 
small amount of force to penetrate the skin, and once the barrier layer has been 
penetrated, the vaccine is rapidly released into the skin. The microscopic wound created 
by the patch is superficial and heals quickly [104]. With the correct excipient conditions 
other vaccines have been stabilized onto a microneedle patch [105, 106]. If this high level 
of temperature stability could be extended to the liv -attenuated measles vaccine, the cost 
and logistical issues associated with vaccine transport and storage could be decreased 
significantly. Finally, the small size of the microneedle patch would limit sharps waste 
following large-scale vaccination campaigns. This would decrease transport costs while 
also minimizing the potential for reuse. 
Measles vaccine has been previously delivered to the skin using a variety of 
methods including the Mantoux method [107] and jet injection [46, 49]. While some 
studies have shown improvements after intradermal delivery [108], others found lower 
neutralizing antibody titers when compared with traditional delivery routes [48, 109]. The 
inferior serologic response to intradermal vaccination seen in these studies could result 
from the low dose of measles vaccine delivered (as low as 5% of the standard dose). 
Neither study investigated the response to a standard subcutaneous dose (at least 103
TCID50) delivered intradermally.  
Stabilization of the measles vaccine in a dry state has also been previously 
examined. Viral infectivity loss after drying has been mitigated through both excipient 
selection and drying process optimization [92, 110]. Some of these dry powder vaccines 
were shown to be efficacious after delivery to the respiratory tract of non-human primates 
[5, 94, 110, 111]. However, these stabilization methods used drying processes such as 
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spray drying and lyophilization, which are not easily compatible with microneedle 
fabrication and coating. 
 Microneedles have been used successfully as an experimental delivery system for 
a number of different vaccines including live virus and bacteria, inactivated virus, virus-
like particles, protein sub-unit, DNA and live viral vaccines against influenza and a 
number of other diseases [2, 13, 17, 20, 23, 80-83, 10  112-116]. However, measles 
vaccine has never been studied before using microneedles. In this study, we first 
examined the ability of excipients to stabilize theliv -attenuated measles vaccine during 
fabrication and storage. We then compared the immune response to vaccination using a 
microneedle patch to conventional subcutaneous inject on in the cotton rat model. 
 
4.2 Materials and methods 
4.2.1 Preparation of live-attenuated measles vaccine 
 
 The measles vaccine strain, Edmonston-Zagreb, was obt ined from the collection 
at the Centers for Disease Control and Prevention and this strain is used in many WHO 
pre-qualified measles vaccines. To achieve the high t ters need for coating of the 
microneedles, the vaccine virus was propagated in Vero cells maintained in Dulbecco’s 
Modified Eagle Medium (DMEM) (Gibco, Grand Island, NY) and 2% fetal bovine serum 
(FBS,Gibco). Infected cells were harvested when the cytopathic effect was maximal; the 
cell suspension was freeze-thawed once before low-speed centrifugation to remove 
cellular debris [117]. The viral titer (50% tissue culture infective dose, TCID50) was 
measured by end-point titration. The virus was then aliquoted and stored at -70oC until 
use. For the end-point dilution assay, 10-fold dilutions of the viral stock were prepared in 
DMEM with 2% fetal bovine serum and used to infect multiple wells of Vero cell 
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monolayers in 24-well tissue culture plates. Plates w re incubated for 7 days and scored 
visually for the presence or absence of viral cytopa hic effect. The TCID50 was then 
calculated using the Karber method [118]. 
 
4.2.2 Vaccine stability studies 
 
 Live measles vaccine virus with an initial viral titer of 106 TCID50/mL was mixed 
with excipients at specific concentrations. Excipients used in this study included 
carboxymethylcellulose (CMC, CarboMer, San Diego, CA), trehalose (Sigma-Aldrich, 
St. Louis, MO), fish gelatin (Sigma-Aldrich), myo-inositol (Sigma-Aldrich), and Lutrol 
F68 (BASF, Mt. Olive, NJ). A 2 µl drop of each resulting solution was applied to a sterile 
chip of stainless steel measuring 3 mm by 4 mm to simulate the surface of a stainless 
steel microneedle. We used this simple method of coating to screen formulations since 
coating actual microneedles is more time consuming. Each 2 µl drop contained a mixture 
of 50% measles virus solution and 50% excipient solution. The chips were allowed to dry 
at room temperature (22 °C) in a Class II biosafety cabinet or an incubator (37 °C). In 
some cases, the air was de-humidified during storage by placing the stainless steel chip 
inside of a 50 mL plastic tube containing desiccant (Drierite, Sigma-Aldrich) and 
wrapped in Parafilm (Sigma-Aldrich). After specified storage times, the vaccine coated 
onto the chips were reconstituted in 1 mL DMEM and viral titers were measured in Vero 
cells as described above.  
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4.2.3 Microneedle fabrication and coating 
 
 Stainless steel microneedles were fabricated by first defining the microneedle 
shape lithographically and then etching the microneedl s in a chemical bath. This 
produced patches each containing a single row of five microneedles that were 750 µm 
long and measured 200 µm by 50 µm at the base (Figure 4). We chose this microneedle 
patch design because the measles vaccine dose is sufficiently small that a full dose can be 
coated onto just five microneedles and because coated microneedles of similar design 
have been successfully used for vaccination and drug elivery in a number of published 
studies [12]. We chose a microneedle length of 750 µm because it matches the thickness 
of rat dorsal skin, which is generally reported in the range of 700 – 1000 µm [119, 120]. 
Thus, we believe vaccine coated on the microneedles was deposited along the needle 
track in the epidermis and dermis; it is possible that a small fraction of the vaccine was 
delivered to the subcutis in the case of thin skin.  
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Figure 4: A five-needle microneedle array next to a U.S. quarter coin with a 
diameter of 24 mm. The arrow points at one of the microneedles mounted on the 
holder. Inset: A single microneedle coated with measles vaccine in a trehalose-based 
coating formulation. 
 
 Based on a method described previously [9], the microneedles were coated with 
live-attenuated measles vaccine by dipping the microneedles 6 times into a coating a 
solution containing 7.5% w/v trehalose, 1% w/v CMC, 0.5% w/v Lutrol F68 and 105.6 
TCID50/mL measles vaccine in sterile DMEM for “full-dose” microneedles. “Low-dose” 
microneedles used a coating solution containing 104.9 TCID50/mL measles vaccine. In this 
way, a five-microneedle array was coated with 1000 TCID50 after full-dose coating and 
with 200 TCID50 after low-dose coating, as determined by dissolving the coatings from 
microneedles and measuring viral titers in Vero cells. The microneedles were stored in a 
sterile container sealed with Parafilm wrap at room te perature in a Class II biosafety 
cabinet for one day before use. 
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4.2.4 Immunization studies 
 
 The immunogenicity of measles vaccination using microneedles was tested in 
cotton rats (Sigmodon hispidus). Cotton rats were divided into seven groups of 5 animals 
each. Groups were assigned as follows: (1) full-dose and (2) low-dose vaccination using 
microneedles (MN); (3) full-dose and (4) low-dose vaccination by subcutaneous injection 
(SC); (5) full-dose and (6) low-dose vaccination by subcutaneous injection of vaccine 
eluted from microneedles (SC*); and (7) sham vaccinatio  using sterile, uncoated 
microneedles.  
Female, 6-week-old cotton rats were allowed at least 5 days to acclimate to the 
animal facility before vaccination. The day before vaccination, blood was collected from 
the rats via cheek bleeding. Animals were anesthetized using a ketamine/xylazine mixture 
during vaccination and blood collection [95]. In the microneedle vaccination groups 
(MN), the hair on the back of each rat was removed using electric shears followed by 
application of a depilatory cream (Nair, Princeton, NJ).  
In the microneedle groups (MN), a microneedle array coated with the desired 
measles vaccine dose was pressed into the skin of the hairless region on the back of the 
animal. Each array was left in the skin for 10 min to ensure complete vaccine dissolution 
from the microneedles for delivery into the skin. Rats in the sham group were treated 
identically, except that no vaccine coating was applied to the microneedles. In the 
subcutaneous vaccination groups (SC), the stock measles vaccine was diluted using 
sterile phosphate-buffered saline (PBS) so that the desired dose was contained in 100 µl, 
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which was then injected subcutaneously using a 25-gauge hypodermic needle on the back 
of the animal. For the reconstituted subcutaneous groups (SC*), ten microneedle arrays 
coated with the desired measles vaccine dose were mixed with 1 ml sterile PBS in a 10 
mL centrifuge tube and vortexed for 2 min to completely dissolve the vaccine. A 25-
gauge hypodermic needle was used to withdraw 100 uL of this solution and inject it SC.    
At the time of vaccination, no adverse effects were noted following any of the 
vaccination methods. A small grid of punctures at the site of microneedle application was 
faintly visible in the skin when the device was removed, but no bleeding was observed. 
Post-vaccination, the microneedle injection sites were examined daily by animal care 
staff and no adverse effects were seen. The small puncture grids were no longer visible 2-
3 days post vaccination and no swelling, discharge or other abnormalities were observed 
at any time point. The hair that had been removed began growing back within one week 
and had returned to normal in all rats by the end of the investigation. 
At multiple time points after vaccination, approximately 500 µL of blood was 
collected from each rat by performing a cheek bleed [95]. After 200 days, the animals 
were anesthetized using a ketamine/xylezine mixture and euthanized by injecting 1 mL of 
Beuthanasia-D (Intervet, Summit, NJ) into the heart. The protocol for the cotton rat 
experiments was approved by the Animal Care and Use Committees of the CDC and the 
Georgia Institute of Technology. 
 
4.2.5 Neutralizing antibody measurements 
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 Measles neutralizing antibody titers in serum samples obtained from the cotton 
rats were determined by the standard plaque reduction neutralization assay [121]. For 




 All statistics were calculated using Prism software version 5.04 (Graphpad, La 
Jolla, CA). Comparisons between individual samples w re done using an unpaired t-test 
with a significance cutoff of p <0.05. For comparison  between 3 or more samples, a two-
way ANOVA with a Bonferroni post-test was used. 
 
4.3 Results 
4.3.1 Vaccine stabilization 
 
 One of the advantages of vaccination using a microneedle patch is that the 
vaccine is stored in a dry state and is administered to the patient without reconstitution. 
When coating microneedles, the thin coating film dries within seconds, leaving no time 
for transfer to a lyophilization chamber. Therefore, it was necessary to optimize 
formulation during this rapid drying step to mainta vaccine viability during patch 
fabrication.  
In a first assessment of virus stability during drying, vaccine stock solution with 
an initial titer of 105.6 TCID50/ml infectivity was dried onto microneedles without 
additives; this resulted in a greater than 10-fold re uction in virus titer (p<0.02; Figure 
5A). Then, excipients were added to the solution to make thick, uniform coatings on the 
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microneedles. Carboxymethylcullose (CMC) was used to increase the solution’s viscosity 
and surfactant (Lutrol F68) to lower surface tensio. These additives (CMC and Lutrol 
F68) in the coating solution destabilized the measles virus even further and reduced the 
TCID50 of eluted virus by more than 100 fold compared to the stock solution (p<0.001; 
Figure 5A).  
 
Figure 5: Effect of coating formulation on measles virus infectivity after drying onto 
microneedle surfaces. Coatings were dried and then stored at room temperature 
(~22oC) and relative humidity (~50%) for (A) 24 h or (B) 1 week. The coating 
solution (CS) contained 2% CMC and 1% Lutrol F68. In (A), all coating solutions 
were prepared using phosphate-buffered saline (PBS). In (B), coating solutions were 
prepared with and without PBS, as indicated on the graph. Asterisk (**) indicates a 
significant difference (p<0.005). Data points represent the average ± standard error 
of the mean (SEM) from n = 3 independently tested samples. 
 
To minimize loss of viral infectivity, a collection of excipients previously shown 
to stabilize lyophilized measles vaccines and approved for use in humans were evaluated 
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[94]. Fish gelatin and the sugar, myo-inositol, provided no significant improvement of 
infectivity compared to the use of coating solution without these additives (p > 0.5; 
Figure 5A). Addition of the sugar trehalose at a concentration of 7.5%, however, 
significantly reduced loss of infectivity compared to the coating solution without 
additives (p<0.005) and the titer of the eluted vaccine was within approximately 1 
log10(TCID50) of the vaccine stock solution (Figure 5A). Unfortunately, after one week of 
storage at room temperature using this formulation (coating solution and 7.5% trehalose 
in PBS), virus infectivity decreased by more than 2 log10 (TCID50) (p<0.03; Figure 5B).  
The coating solutions used so far were all prepared in PBS. To address possible 
osmotic effects, a coating solution was prepared with trehalose but without PBS. Use of 
this coating solution significantly increased stability relative to the saline-containing 
solution (p<0.005) and resulted in a loss of just 0.8 log10(TCID50) after drying and 
storage at room temperature and ambient humidity for 1 week (Figure 5B). This 
formulation containing trehalose and lacking PBS was used for all remaining experiments 
in this study.  
The current WHO standard for stability of lyophilized measles vaccine is less than 
1 log10(TCID50) unit of infectivity loss after 30 days at 25oC or 1 week at 37oC [122]. The 
next set of experiments was designed to determine if measles virus coated onto 
microneedles could meet the WHO standard. These tests were performed with the 
addition of desiccant to control for humidity. First, a control sample of virus diluted in 
standard DMEM was seen to rapidly lose activity at 25oC and no infectivity was reported 
by the 1 week time point. Following the addition of the stabilizing solution, samples dried 
at room temperature exhibited a viral titer loss of 0.57 log10(TCID50) units of infectivity 
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after 30 days of drying at 25oC. At 37oC, the loss in viability after one week was 0.85 
log10(TCID50), although longer exposure resulted in additional loss of viability up to 2.91 
log10(TCID50) (Figure 6). Therefore, the optimized coating formulation developed in this 
study was sufficient to meet one of the WHO standards for measles vaccine stability, 
although further improvements in stability would bed sirable and are currently being 
evaluated.  
Figure 6: Loss of measles virus infectivity over time as a function of formulation and 
storage temperature. Coatings were dried at room temperature and humidity and 
then stored in sealed pouches with desiccant for 30 days at 25oC or 37oC. 
Formulations included no additives (i.e., no coating solution or trehalose) and 
coating solution (CS) with 7.5% trehalose. Data points represent the average ± SEM 
(N = 3). The data points for the 10, 17 and 30 day time points for the 25oC samples 
had a SEM of 0 because all replicates had the same values. 
 
 37
4.3.2 Immunization studies 
 
 The immunogenicity of measles vaccination using a microneedle-based vaccine 
was evaluated in the cotton rat. This animal model was chosen because it is a well-
studied, small-animal model for measles viral infection and is commonly used in measles 
vaccination experiments [123]. The goal of the study was to compare the immunogenicity 
of measles vaccination using a microneedle patch wit the immunogenicity of the same 
vaccine dose delivered by subcutaneous injection. Oe group (n=5) received 
subcutaneous injection (SC) as a positive control to represent the current approach used 
in human vaccination. A second subcutaneous group received an injection containing 
measles vaccine that had been dried on a microneedle patch and reconstituted in PBS 
prior to subcutaneous injection (SC*). This group was included to account for the 
possible loss of immunogenicity of the measles vaccine during fabrication of the 
microneedle patches independent of the route of administration. The microneedle group 
(MN) received a single microneedle patch applied to the skin of the back. Groups were 
immunized either with a standard human dose of measles vaccine (1000 TCID50) or a 
reduced dose (20% of standard dose, 200 TCID50) to investigate possible dose-sparing 
associated with vaccination in the skin. 
All vaccinated animals demonstrated a detectable antibody response after day 20. 
Additionally, in all vaccinated groups (MN, SC, SC*) at both doses, the time course of 
the neutralizing antibody response was similar (Figure 7). At the day 10 time point, both 
MN groups had statistically higher titers than the subcutaneous controls at the same dose 
(p<0.005). This suggests that microneedle delivery of the measles vaccine may generate a 
more rapid antibody response than subcutaneous injection, but this observation needs to 
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be tested further. Peak neutralizing antibody titers occurred in all groups at approximately 
30 days post vaccination with no statistically signif cant differences in titer observed 
(Table 1, p>0.05). The peak titers achieved in all v ccinated groups were statistically 
indistinguishable among the standard dose groups (Table 1, Figure 7A, p>0.05) and 
among the reduced dose groups (Table 1, Figure 7B, p>0.05). All vaccinated groups 
achieved peak titers significantly greater than the s am control group (p<0.005), which 
had no detectable neutralization activity.  
 Blood was also collected 200 days after vaccinatio t  examine long-term 
antibody responses. Both the MN (full dose) and SC (full dose) groups showed a 
statistically significant decrease in titer from the peak over time (p<0.05). It is notable; 
however, that neutralizing antibodies were detected in all vaccinated groups more than 6 
months after immunization. Peak titers among the MN and SC groups vaccinated with the 
standard dose were approximately three-fold greater than those among MN, SC and SC* 
groups vaccinated with the reduced dose (Table 1, p<0.005). 
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Figure 7: Neutralizing antibody responses after vaccination using microneedles 
compared to subcutaneous injection. Cotton rats wer vaccinated with (A) a full 
human dose (1000 TCID50) or (B) 20% of a full human dose (200 TCID50). 
Vaccination was performed with microneedles (MN), subcutaneous injection of 
unprocessed vaccine (SC), subcutaneous injection of vaccine coated onto 
microneedles and reconstituted before injection (SC*) or as a sham vaccination 
using microneedles with a vaccine-free coating. Antibody titers were determined by 
plaque neutralization. Blood was collected from each animal at the given time points 











Table 1: Immune response characteristics of measles vaccination using 
microneedles. 
Group 2 
TMAX ± SEM 
(days) 3 
Peak titer  ± SEM (log 2 
antibody titer) 
Day 200 Titer ± SEM ( log 2 
antibody titer) 
SC (Full) 32 ± 4.9 6.8 ± 0.2 4.6 ± 0.6 
SC* (Full) 32 ± 3.7 6.0 ± 0.3 4.8 ± 0.6 
MN (Full) 28 ± 2.0 6.8 ± 0.2 5.4 ± 0.2 
SC (20%) 24 ± 2.4 5.2 ± 0.2 2.2 ± 0.6 
SC* (20%) 20 ± 0.0 4.6 ± 0.4 3.0 ± 0.0 
MN (20%) 26 ± 2.4 5.6 ± 0.2 3.6 ± 0.8 
 
1 Reported values were determined from antibody timecourse data for each animal 
and then averaged. The corresponding average antibody timecourse data are shown 
in Figure 7.  
2 Vaccination was performed by subcutaneous injection of unprocessed vaccine 
(SC), subcutaneous injection of vaccine coated onto microneedles and reconstituted 
before injection (SC*) or microneedles (MN) using the full human dose (Full) or 
20% of the human dose (20%) 




The goal of this study was to evaluate a microneedle patch for delivering measles 
vaccine. The microneedles were designed to be applied as a skin patch without the need 
for reconstitution. In contrast to conventional subc taneous injection, administration of 
the microneedle patch should require minimal training, and therefore, reduce the need for 
injections by highly trained healthcare professionals. This simple delivery method could 
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reduce the cost of vaccination, and facilitate mass vaccination campaigns aimed at 
achieving regional measles elimination and future eradication 
The microneedle patch was also designed for cost-effective manufacturing. The 
vaccine-free microneedle patches can be mass produced at a cost that should be similar to 
or even less than the cost of a needle and syringe. Coating vaccine onto microneedle 
patches was carried out as a simple, automated, dip-coating process that can readily be 
scaled up for low-cost mass production as well. Indeed, microneedle patches coated with 
parathyroid hormone have already been manufactured commercially and used in Phase I 
and Phase II human clinical trials [124]. For these reasons, we anticipate that mass-
produced microneedle vaccine patches may be manufactured at cost similar to 
conventional lyophilized measles vaccine. However, as a single-dose presentation, 
microneedle patches should reduce the extensive wastage currently associated with 
measles vaccine in multi-dose vials [65].  
In this study, immunogenicity after measles vaccinatio  using microneedles was 
statistically indistinguishable from vaccination bythe traditional subcutaneous route in 
the cotton rat model, including the time course of the immune response, peak titers and 
titers measured >6 months after vaccination. This show  that vaccination using a 
microneedle patch can induce an antibody response to measles virus that is equivalent to 
the response following standard subcutaneous injecton. Though the optimal animal 
model for evaluating measles vaccines is the rhesus macaque [5], cotton rats were chosen 
for this study because they provided a low cost, small animal model for evaluating the 
ability of the microneedle vaccines to reconstitute in vivo and generate a neutralizing 
antibody response. Cottons rats are an accepted small animal model for measles, and this 
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model has been used in many research projects. Both vaccine and wild-type strains of 
measles have been shown to replicate in cotton rats [123].   
In this study, a vaccine coating formulation was developed that enabled vaccine-
coated microneedles to meet the accelerated stability criterion of the WHO, i.e., storage 
for 1 week at 37oC while retaining at least 10% virus viability [122]. Removal of the salts 
in PBS, which probably reduced osmotic stresses during drying, and addition of the sugar 
trehalose, which is believed to stabilize vaccine atigen structure, maintained vaccine 
virus viability for 1 month at 25oC in the presence of desiccant.  
The use of trehalose in the coating formulation was important to maintaining 
stability of the measles virus. This disaccharide has been widely used as a stabilizer in 
many different biological systems [125-127]. It is thought that trehalose replaces the 
water around hydrophilic protein regions during drying, thereby preventing protein 
denaturation [128].Other stabilizers tested in thisstudy were not effective. Fish gelatin 
and myo-inositol were chosen because they are included in the formulations of other 
currently available vaccines and they have been shown t  have stabilizing effects on 
measles virus in the literature.[94]  
A dose-sparing effect has sometimes been seen when using microneedles with 
other vaccines [21, 129], but dose sparing was not seen in this study with the measles 
vaccine at the doses used. As the mechanism of dose sparing in the skin is still under 






This study compared administration of live-attenuated measles vaccine using a 
microneedle patch to conventional subcutaneous inject on for the first time. We showed 
that the measles virus can be coated and dried onto me al microneedles with acceptable 
stability during storage. Vaccination of cotton rats showed that microneedle vaccination 
produced antibody titers similar to vaccine delivered using a conventional subcutaneous 
injection. However, unlike subcutaneous injection, measles vaccination with a 
microneedle patch is rapid and simple to administer, which could dramatically decrease 
the training required for measles elimination campaigns [130]. The patches themselves 
are small and lightweight, easy to dispose of, and expected to require low-cost 
manufacturing in mass production. We conclude that delivery of measles vaccine with a 
microneedle patch can be efficacious and could provide a means to significantly increase 
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CHAPTER 5  Discovering stabilizing excipients for the measles 




Measles is a highly infectious respiratory disease that still kills more than 150,000 
people worldwide [117]. The primary way to prevent infection is successful vaccination. 
Since its introduction in the 1960’s, the live-attenuated measles vaccine has led to 
significant advancements in the fight against measles [131]. Endemic measles was 
eliminated from the Americas in 2002 and currently 4 of the 5 WHO regions have set 
elimination goals [117]. It has been estimated thatinterruption of measles transmission 
requires vaccine coverage rates in excess of 90% [132]. This high bar requires a 
coordinated effort between vaccine manufacturers, public health experts and delivery 
personnel in the field. Effective vaccination also requires an effective vaccine. While the 
live-attenuated measles vaccine is extremely effectiv  when given correctly, storage 
requirements can impede widespread dissemination. Additionally, the vaccine is known 
to rapidly lose activity when exposed to elevated tmperatures, even in its lyophilized 
state. The WHO estimates that due to spoilage, mishandling, or improper reconstitution 
more than 60% of the measles vaccine delivered into the field is not utilized [133]. Even 
for a product as inexpensive as measles this can lead to significant increases in the cost of 
mass vaccination campaigns. Increasing the stability of the live-attenuated measles 
vaccine would decrease this wastage and ultimately result in more product available for 
eventual administration. 
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The traditional method for determining the titer of live-virus vaccines is some 
form of plaque assay. This typically requires infection of a monolayer of cells followed 
by incubation, staining and analysis. The standard unit of infectivity for the measles 
vaccine is the 50% tissue culture infectivity dose [121]. This assay requires a 5-7 day 
incubation time and then manual identification of the resulting plaque formation. It has 
been shown that the same measles sample read by different labs and personnel can result 
in nearly a 1 log unit difference in reported titer [134]. This type of assay does not easily 
lend itself to a high-throughput screen of excipients for the purposes of increasing 
measles viral stability. 
 The introduction of a genetically modified measles virus has opened up new 
avenues for infectivity detection. An altered measls virus strain (eGFP-MeV) was 
created which encodes the genetic material for green fluorescent protein [96]. Following 
infection, viral replication causes the production f eGFP. This makes it possible to 
detect measles activity rapidly using the resulting fluorescence. This virus has been 
previously used to examine viral stability in a large-scale screening study [98]. The 
previous technique was complicated by a number of additional steps including the 
addition of an agent which prevents cell fusion. It also required computer software to 
count and analyze the halted viral propagation. An assay which could simplify the 
process of measuring fluorescent activity after infection would be a positive 
development. 
 The goal of this study was to discover excipients which could improve the 
stability of the live-attenuated measles vaccine. I order to accomplish this a new assay 
was created which utilized eGFP-MeV to measure measles infectivity quickly, efficiently 
and reproducibly. Using this assay, a screen was performed to determine the stabilizing 
activity of a number of commercially available excipients. 
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5.2 Materials and methods 
5.2.1 Propagation of eGFP-measles vaccine virus 
 
 Measles vaccine virus that had been genetically engin ered to produce eGFP 
during replication was acquired from the lab of Dr. Paul DuPrex at Boston University 
[97]. This stock was then propagated in Vero cells as previously described to increase the 
viral titer [122]. The final titer was measured using a TCID50 assay to be 3.0 x 105 viral 
units/mL. 
 
5.2.2 Selection of excipients 
 
 The excipients used for the screening portion of this study were selected based on 
a number of characteristics. A through literature search resulted in an initial list that had 
been specifically shown to stabilize the live-attenuated measles vaccine virus. This list 
was further expanded by adding additional compounds which had been shown to stabilize 
other vaccines, including excipients found in commercially approved vaccine 
preparations. The final list also included compounds that had not been previously studied 
in vaccine stabilization experiments. These were sel ct d by expanding the number of 
certain types of compounds that already appeared on the list in high numbers. This 
resulted in the addition of a significant number of carbohydrate substances and amino 
acids. All excipients chosen for this study either appear on the Generally Regarded as 
Safe (GRAS) list or are already approved for injection into humans. The final excipient 
list contained 46 different compounds or concentrations of compounds (Table 2). All 
listed percentages represent a weight/volume percent. 
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5.2.3 Green fluorescent protein infectivity assay 
 
 All excipient formulations were mixed in a 1:1 ratio with a stock of eGFP-
measles vaccine virus (eGFP-MeV) with a titer of 3.0 x 105 TCID50/mL. A 3 µL sample 
of this formulation was then coated onto stainless steel chips in a manner previously 
described [122]. These chips were placed into 1.5 mL centrifuge tubes (Epindorf, 
Hauppauge, NY). The samples were then placed into a p que bag along with color-
changing desiccant (Drierite, Sigma-Aldrich, St. Louis, MO). The bag was then sealed 
using a heat sealer to prevent against moisture contami ation. All samples were dried for 
24 hours at 22oC in a fume hood before storage. After removal from storage the desiccant 
of each sample was checked for indication of moisture. If any contamination was 
detected the sample was discarded. 
 Each centrifuge tube, which contained a single drid measles virus preparation, 
was filled with 1 mL of a solution of Dulbecco’s Modified Eagle Medium (DMEM) 
(Gibco, Grand Island, NY) containing 2% fetal bovine serum (FBS, Gibco). This was 
then vigorously mixed to re-suspend the dried viral sample. The samples were tested for 
fluorescent activity using 96-well plates (Immunolon 2HB, Thermo Scientific, Waltham, 
MA) containing a monolayer of Vero cells. To each well in the plate, 100uL of the 
reconstituted viral solution was added. The plates w re incubated for 72 hours at 37oC to 
encourage viral propagation. After incubation each well was washed with 300 uL of 
sterile phosphate-buffered saline (PBS, Sigma-Aldrich) to remove media and uninfected 
viral particles. Any remaining solution was aspirated from the wells before testing. 
Detection of florescence was accomplished by measuring each well using a 96-well plate 
reader with an excitation wavelength of 485 and an emission wavelength of 520. The 
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detected signal of each sample was compared to a positive control containing the same 
concentration of liquid eGFP-MeV. 
 
5.2.4 Stabilizing excipient screen 
 
 A first screen was performed to investigate the ability of all of the excipients 
selected to prevent infectivity loss in a dried preparation of measles vaccine virus. Each 
sample was mixed to the concentration indicated and dried with a solution of measles 
vaccine virus as described above. For the initial screen, each prepared sample was stored 
in an incubator at 37oC for 7 days. After testing for eGFP expression each sample was 
then ranked based on percent of activity remaining as compared to a liquid control 
sample of eGFP-MeV. A cutoff value of 10% remaining activity was chosen to eliminate 
samples with minimal stabilizing activity. 
 A subset of the initial excipients was then subjected to a more stringent secondary 
screen. Theses samples were prepared and stored for 1 m nth at 37oC. After storage the 
samples were tested and ranked according to remaining activity. The results from this 
storage condition led to the addition of excipient combinations to the testing regimen. 
The combinations of excipients were tested at the same storage time and temperature 
conditions as the secondary screen. After eGFP florescence detection a cutoff value of 
40% remaining activity was chosen for advancement to the final storage condition. 
 The final screen was performed by storing samples for 1 month at 45oC. The 
results from this screen resulted in the final excipient combination which was then 
subjected to a variety of temperature and storage conditions. 
 
5.2.5 Extended storage study 
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 A stabilizing solution consisting of 300 mM of threonine (Sigma-Aldrich) and 
15% w/v sucrose (Sigma-Aldrich) in DI-H2O was created for the final storage 
experiment. Samples were created using the method described above and stored at 4oC, 
22oC and 45oC for between 1 and 24 weeks. A control consisting of a dried sample of 




 All statistics for this study were calculated using Prism software version 6.02 
(Graphpad, La Jolla, CA). Comparisons between indivdual samples were done using an 
unpaired t-test was a significance cutoff of p<0.05. Comparisons between multiple 
samples was done using a two-way ANOVA with a Tukey post-test and a significance 
cutoff of p<0.05. The exponential best fit line was determined using Excel 2013 




5.3.1 Assay development 
 
 Before proceeding to the stability screen, initial experiments were performed to 
better understand the parameters of the eGFP assay. Multiple 96-well plates containing 
confluent layers of Vero cells were infected with decreasing concentrations of eGFP-
MeV and then allowed to incubate for 2, 3 or 4 days to examine how florescence activity 
changed over time. The initial eGFP-MeV titer used was measured to be 500 TCID50/mL. 
The goal was to determine the shortest incubation time which still delivered a robust 
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florescence curve. The florescent activity was measured using the method described in 
Section 5.2.3. The results show that after 3 days of incubation there is a linear correlation 
between viral concentration and florescent intensity tarting at a concentration of 250 
TCID50/mL (Figure 8). As a result, we used an incubation me of 3 days and a maximum 
viral titer of 250 TCID50 per sample for all stability experiments. 
 
5.3.2 Stability screen 
 
Figure 8: Development of the eGFP-MeV assay. 
A dilution series of eGFP-MeV was used to infect a confluent layer of Vero cells. 
The infected cells were allowed to incubate for 2, 3 or 4 days. At that time the cells 
were washed and the florescence was measured. The results show that after 3 days 
of incubation florescence has a linear relationship to viral titer beginning at a 
concentration of 250 TCID50/mL. Each point represents the average (N = 2) ± SD. 
The red line indicates a linear best fit curve excluding data collected from the 500 
TCID 50/mL sample. The R2 value was calculated to be 0.992. 
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 In order to rapidly assess the stabilizing potential of the initial list of excipients, a 
high temperature, short time storage study was performed. The goal of this study was to 
eliminate any excipients which had minimal or no detectable effect on vaccine activity. 
 As expected, the initial screening study resulted in the elimination of the vast 
majority of the chosen excipients. After storage, approximately 41% of the tested samples 
retained less than 1% of their initial activity. The cutoff value of 10% remaining activity 
Figure 9: Initial screen of excipient using eGFP-MeV assay. 
The initial list of excipients was screened for stabilizing activity using the eGFP-
MeV assay. Samples were dried overnight and stored for 1 week at 37oC with 
humidity control. After storage each sample was incubated in cell culture for 3 days 
and then assayed for fluorescence activity. Each bar represents a comparison
between the detected fluorescence of a control MV sample and a dried sample. The 
dotted line represents the cutoff point of 10% remaining activity after storage. Each 
sample was tested once to maximize throughput. 
 
 53
was chosen because it corresponds to the WHO requirement for live-attenuated measles 
vaccine stored for 1 week at 37oC [118]. This resulted in the elimination of about 61% of 
the initial list (Figure 9). After the initial screen, 14 samples were chosen for further 
investigation in the second screening experiment. 
 In order to further assess the stabilizing potential of the remaining excipients, a 
longer storage condition was chosen for the second screen. Since the goal of this study 
was to produce a single excipient mixture for long-term evaluation, the secondary screen 
attempted to eliminate all of the excipient which could not significantly stabilize eGFP-
MeV under these revised conditions. After 1 month at 37oC, only 4 samples demonstrated 
remaining activity of more than 1% (Figure 10). During this secondary screen we noticed 
that when the excipients glycine and sucrose were tsted individually they exhibited 
extremely low stabilizing activity (0.53% and 0.61% respectively). When these excipient 
were added together their ability to stabilize eGFP-MeV increased significantly to 
30.45% (p<0.0005) (Figure 11). This led us to investigate the effect of using a 
carbohydrate sugar and an amino acid in combination to stabilize the measles vaccine. 
Combinations were made of all excipients in these two categories that exhibited any 
stabilizing activity during the initial screen. This resulted in 21 combinations. All of the 
amino acids were also tested individually to serve as a control. After storage for 1 month 
at 37oC the results confirmed our earlier observation. Every amino acid tested exhibited a 
higher stabilizing ability when paired with a carbohydrate sugar (Figure 12). Sucrose was 
the most potent secondary stabilizer. Combinations including sucrose had the highest 
remaining activity for 6 of the 7 tested amino acids. A cutoff limit of 40% was used for 






Figure 10: Secondary screen of excipients using eGFP-MeV assay. 
After removal of low-performing excipients a second screen was performed. These
samples were prepared in the same manner as before and stored for 1 month at 
37oC. After storage the samples were incubated in cell culture for 3 days and then 
assayed for fluorescent activity. The percentage represents a comparison between 
the fluorescent activity of a control samples of eGFP-MeV and the dried samples.
Each bar represents the average (N = 3) ± SD. 
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Figure 11: Effect of combining excipients on their overall stabilizing ability. 
It was determined that a combination of glycine and sucrose had significantly 
higher stabilizing ability than either excipient possessed individually. The bar 
represents the average (N = 3) ± SD. Asterisk (****) indicates a significant 
difference (p<0.0005) as determined by ANOVA. 
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 A final screen was carried out to determine the best combination of excipients to 
use for more extensive stability experiments. After storage for 1 month at 45oC the 
remaining activity of each sample was tested. This screen showed that a combination of 
the amino acid threonine and the sugar sucrose had the highest stabilizing potential 
(Figure 13). This combination was able to retain nearly 14% of its original activity after 
storage at this harsh temperature condition. 
 
Figure 12: Stabilizing ability of excipient combinations tested with an eGFP-MeV 
assay. 
All possible combinations of amino acids and sugars that had previously shown 
stabilizing activity were made. These samples were tested and compared to 
individual amino acid solutions. The bars represent he average (N = 3) ± SD. 
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5.3.3 Extended storage study 
 
 After screening, the highest performing excipient mixture was subjected to a 
longer term study to further examine its ability to maintain the infectivity of eGFP-MeV. 
Samples were stored at a range of temperatures for up to 2 month. After storage for 1 
week at room temperature (25oC), the control sample which included no stabilizing 
excipient had lost 100% of it infectivity as measure sing the eGFP assay. Samples which 
included the stabilizing solution (threonine + sucrose) performed much better (Figure 14). 
After some initial detected loss at the 1 week time point, the samples stored at 4oC and 
Figure 13: Final excipient screening study using eGFP-MeV assay. 
Excipient combinations that showed potent stabilizing activity in the previous 
screen were subjected to a higher storage temperature. These samples were dried 
and stored for 1 month at 45oC. After storage the samples were incubated in cell 
culture for 3 days and then assayed for fluorescence. The activity represents a 
comparison between the detected fluorescence of a control stock of eGFP-MeV and 
the dried samples. The bars represent the average (N = 3) ± SD. 
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25oC retained on average 95% and 89% of their activity respectively after 1 month of 
storage. Samples stored at the higher temperature (45oC) had significantly higher loss at 
this time point. They retained only 32% of their infectivity as measured using eGFP 
florescence detection. At the final 6 month time point, the samples stored at the 2 lower 
temperatures proved to be very stable. The 4oC and 25oC samples retained 100% and 
90% of their original infectivity respectively. The samples stored at 45oC maintained less 
than 1% of their infectivity at this time point. The rate of decay for the 45oC sample as 
calculated by an exponential best-fit line with an R2 = 0.9961 was found to be k = -0.216. 
The rate of decay for the 4oC and 25oC samples was not calculated because they had not 
lost a significant amount of activity by the 6 month time point. 
 
Figure 14: Extended stability of threonine-sucrose formulation. 
The best performing formulation from the final screening study (threonine + 
sucrose) was added to eGFP-MeV and stored for 0 – 24 weeks at three different 
temperatures. A samples of eGFP-MeV without excipients was also dried and stored 
at 25oC. All samples were compared to a liquid control of eGFP-MeV to obtain the 
stability percentage. The samples stored at 4oC and 25oC retained more than 90% of 
their activity. The samples stored at 40oC had greater activity loss over time. The 





 Measles vaccine spoilage represents a significant problem for large-scale 
vaccination campaigns. The WHO estimates that more than 50% of all possible vaccine 
doses are never delivered due to handling error or sp ilage [135]. Wastage of measles 
vaccine in particular is even more acute. A study in Bangladesh found that on average 
70% of possible measles doses were wasted due to spoilage or reconstitution error [133]. 
Increasing the ability of the measles vaccine to withstand adverse temperature conditions 
could greatly reduce these levels of waste.  
 Stabilization of the live-attenuated measles vaccine has been previously studied 
[92, 94, 98]. Ohtake et al examined a variety of excipient combinations for their effect on 
measles vaccine stability following a traditional spray drying procedure. They found that 
many compounds expected to decrease vaccine loss at elevated temperatures such as 
surfactants, ions and plasticizers did not have a bneficial effect. It was discovered that 
the addition of arginine, an amino acid, to the stabilizing formulation resulted in a 
significant increase in stability after 4 weeks of drying. Their best formulation also 
included sucrose, potassium phosphate and human serum albumin. Their final drying 
condition of 12 weeks at 37oC resulted in an infectivity loss of approximately 1.2 
log10(TCID50). The stability of liquid measles has also been studied by Schlehuber et al 
[98]. Their best excipient formulation also included amino acids (glycine and serine) and 
sugars (trehalose and sucrose) in addition to a buffering agent (tricine) and a few other 
compounds. With this formulation they were able to limit activity loss to less than 0.4 
log10 after 8 hours of incubation at 37oC as measured by an eGFP-MeV assay. This result 
corresponded well to the same formulation measured sing a traditional TCID50. After 
the same 8 hours of incubation the detected loss using this assay was 0.5 log10. 
 Remaining water content after drying has also been shown to be important to 
measles vaccine stability. Burger et al measured th remaining water content of the 
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measles vaccine following the use of a novel bubble-drying procedure [94]. They found 
that depending on the excipient formulation and process conditions the final water 
content could range from 0.5% to greater than 1%. They hypothesized that minimizing 
the amount of water left in the sample would have a beneficial effect on long-term 
vaccine stability. 
  Drying under ambient temperature and pressure is an alternative that has not been 
well studied. Many vaccine delivery systems such as microneedle patches are not well-
suited to compounds dried using spray drying, lyophilization or similar methods. This 
study examined the ability of commercially available, human-approved excipient 
compounds to stabilize the measles vaccine after drying and subsequent storage. Another 
goal of this study was to develop a high throughput assay to aid in the rapid screening of 
excipients. 
 The current method of determining the titer of them asles vaccine is by a 50% 
tissue culture infectivity dose (TCID50) assay. This assay is both time-consuming and 
uses a large quantity of materials. Each sample requires the use of a single 24-well plate, 
with requirements increasing when samples are run in duplicate or triplicate. This assay 
has also been shown to have a high level of variability from test to test. A collaborative 
study found that laboratory variability when testing the same sample of measles vaccine 
was as high as 1 log(TCID50) unit [134]. This range could cause major problems for a 
study attempting to examine vaccine potency measurements at a variety of storage 
conditions. This study utilized a measles vaccine virus variant which has been engineered 
to express green fluorescent protein during replication [96]. This vaccine virus has been 
previously using in a high throughput assay for similar purposes [98]. That assay utilized 
a number of additional steps including chemical inhibition of cell fusion post-infection 
and computer-aided detection of florescent plaque formation. That assay measured total 
infected cells rather than overall florescence. This study shows that simple florescence 
detection after infection can reliably demonstrate th  infectivity potential of dried 
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samples after reconstitution. Using this assay, a variety of different excipients were 
rapidly screened for the presence or absence of stabilizing activity. 
 Over the course of the screening experiment, an interesting phenomena was 
observed. Excipient formulations which contained both a sugar and an amino acid 
demonstrated far superior stabilizing potential than either of the excipients showed when 
tested individually. Many commercial vaccine solutions include a compound from each 
of these categories but to date there have been no study which directly showed this 
synergistic response. The ability of amino acids to stabilize proteins has been well-
studied [136]. Glycine, for example, has been shown to i crease the melting temperature 
of model proteins such as bovine serum albumin (BSA) by up to 13oC [137]. It has been 
hypothesized that the amino acids react indirectly, reating a preferential hydration state 
that allows the protein to maintain a minimum level of water contact even after drying 
[138]. It is also well known that sugars can have a stabilizing effect on proteins. Microbes 
which can maintain activity after extreme water loss have been known to increase their 
intracellular trehalose concentrations as a coping mechanism [139]. The many hydroxide 
groups present on this and other sugars have been shown to interact directly with proteins 
and lipids, taking the place of water around the hydrophilic domains [128]. This allows 
for the maintenance of the native “wet” state even in the absence of water. 
 It is possible that the stabilizing effect seen in this study is a result of both of these 
phenomena acting in concert. The amino acid in the solution may be increasing the 
protein’s ability to accept hydration. This allows for the sugar molecules to more easily 
replace water around the hydrophilic domains as the sample dries. More work needs to be 






 A method which could stabilize the measles vaccine to prevent spoilage would be 
a major benefit for the global measles elimination campaign. Vaccine wastage represents 
a serious problem, impeding efforts to increase the reach of these campaigns away from 
population centers. This work shows that by using a high-throughput assay, excipients 
which stabilize the live-attenuated measles vaccine aft r drying can be found. The best 
formulation, consisting of a mixture of threonine and sucrose, was able to completely 
mitigate infectivity loss at 4oC and 25oC. It was also able to maintain more than 10% 
activity at 45oC for more than 8 weeks. These advances could allow for future 
microneedle patch systems which incorporate measles vaccine to be more stable at 
elevated temperatures, mitigating current cold chain requirements. Future work will 
attempt to increase stability even further towards a goal of removing measles vaccine 
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 In the past decade, substantial progress has been made in the fight against 
measles. Since the year 2000, deaths from measles have decreased by more than 82%. 
They have fallen from more than 850,000 to an estimated 158,000. This sustained 
decrease in mortality is due in large part to the avail bility of a safe, cheap and effective 
vaccine. The live-attenuated measles vaccine costs just $0.10 to produce and has efficacy 
rates approaching 90% when two doses are given [131]. A plan to implement high levels 
of  two-dose coverage in the WHO Region of the Americas led to the elimination of 
measles in 2002 [117]. By 2012, 4 of the 5 remaining WHO regions had set a goal for 
measles elimination by, or before 2020. Unfortunately, the drive towards measles 
elimination has stalled in recent years. This is prima ily due to the highly infectious 
nature of measles. It is estimated that coverage rates in excess of 95% are required to 
interrupt viral transmission [4]. Increasing global measles vaccine coverage is the only 
way to continue current reductions in measles morbidity and mortality. 
 In 2012, the research priorities for global measles control and eradication were 
published and these included improved vaccine delivery methods [140]. In resource 
limited settings, the traditional vaccine delivery methods have can pose significant 
logistical drawbacks. Currently, the measles containing vaccine must be administered by 
hypodermic injection. This necessitates the need for trained personnel to deliver each 
dose of vaccine. Compared to using minimally trained volunteers, this requirement 
significantly increases the cost of a mass vaccinatio  campaign while simultaneously 
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decreasing its scope. Door to door vaccinations, which are used for the oral polio vaccine, 
are simply not conducive to injectable vaccines. 
 Needle and syringe delivery also creates safety hazards for both the vaccinator 
and patient. Sharps and other medical waste must be properly disposed of to avoid 
disease transmission or needle reuse. Even small vaccination campaigns can generate 
significant amounts of medical waste [102]. Transport and storage of this byproduct 
constitutes a significant portion of the overall cost f large public health projects such as 
measles elimination. 
 Finally, the lyophilized measles vaccine is typically packaged in multi-dose vials 
which must be kept in the cold chain, reconstituted prior to use, and discarded within 6 
hours after reconstitution. Errors in reconstitution of the vaccine, as well as the need for 
refrigerated storage can lead to significant vaccine wastage [95]. A technology which 
could mitigate the need for the cold chain has the pot ntial to drastically lower the cost 
and complexity of mass delivery of the measles vaccine. 
 An innovative delivery method which could alleviate many of the problems 
associated with syringe injection is the microneedl patch. Microneedle patch systems 
have the potential to substantially improve vaccine delivery. Microneedles are micron-
scale (<1000 µm), solid or dissolving needles containing a dry formulation of vaccine 
that rapidly dissolves in the skin upon patch application [13]. Numerous vaccines and 
other biologics have previously been delivered using microneedle systems [15-17, 19, 22, 
82, 87, 101, 115, 141]. The simplified application provided by a microneedle-based 
measles vaccine could move trained medical personnel, a limited resource in developing 
countries, into a supervisory role leaving vaccinations to be performed by minimally-
trained personnel. Microneedle patches cause little or no pain and can adhere to the skin 
in a manner as easy as applying a bandage. Microneedle patches would also be 
formulated to deliver a single dose without the need for reconstitution. This limits 
vaccine waste associated with errors in reconstitution such as using expired or incorrect 
 65
reconstitution fluid. Additionally, microneedles may llow for less stringent cold-chain 
requirements, minimizing vaccine spoilage. The microneedle vaccine patch is also 
expected to require lower packaging requirements compared to the current combination 
of lyophilized vaccine, hypodermic needles and reconstitution vials. This advancement 
would require less storage, transportation, and disposal capacity. These benefits could 
greatly enhance current efforts to attain the high vaccination coverage needed to achieve 
measles elimination goals. 
 In this study, the live-attenuated measles vaccine was delivered for the first time 
using a dissolving microneedle patch in a rhesus macaque. This vaccination route was 
then compared to the same dose delivered using a traditional needle and syringe. 
 
6.2 Materials and methods 
6.2.1 Preparation of live-attenuated measles vaccine 
 
 The Edmonston-Zagreb measles vaccine strain was acquired from the collection 
at the Centers for Disease Control and Prevention. The viral stock was then propagated in 
Vero cells to increase the titer as previously described [122]. 
 
6.2.2 Microneedle fabrication 
6.2.2.1 Creation of microneedle mold 
 
 Molds consisting of a 10 x 10 array of 300 x 300 x 600 µM pyramidal 




6.2.2.2 Measles vaccine filling 
 
 Measles vaccine solution at a titer of 1.0 x 105 was added in a 1:1 ratio to a 
solution consisting of 15% w/v sucrose (Sigma-Aldrich, St. Louis, MO), 300mM 
threonine (Sigma-Aldrich) and 2% w/v carboxymethyl cellulose (Sigma-Aldrich). This 
solution was mixed and applied to the microneedle mold. The solution was spread using a 
pipet tip to ensure the entire mold surface was covered. This mold was then placed on 
custom-made vacuum system and suction was pulled from the bottom of the mold at a 
pressure of approximately -3.59 kPa for 20 minutes. The mold was removed from the 
vacuum system and allowed to dry for 40 minutes. At this time any vaccine solution 
remaining on the surface of the mold was removed by tape stripping. 
 
6.2.2.3 Polymer matrix filling 
 
 To create the matrix for the dissolving patches, 8 g of sucrose (Sigma-Aldrich) 
and 8 g of poly-vinyl alcohol (Sigma-Aldrich) was mixed into 15 mL of DI-H2O. This 
solution was then heated at 60°C for 3 hours. The solution was allowed to cool overnight 
at 25°C. The PVA/sucrose matrix material was spread in a thin layer over the 
microneedle mold using a spatula. Care was taken to ensure that the entire mold surface 
was covered. The molds were placed back into the vacuum system and suction was 
applied at a pressure of -3.59 kPa for 60 minutes. The molds were then allowed to dry for 
48 hours at 25°C in a fume hood. To remove the needle patches, a circle of dextrin 
(Sigma-Aldrich) was coated with double-sided tape (MacTac, Stow, OH) and applied to 
the back of the mold. This disc was gently peeled away from the PDMS mold, taking care 
to prevent damage to the needles. The completed microneedle patches were then 
lyophilized for 24 hours to strengthen the needles and remove any remaining water. 
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Patches were stored in a sealed pouch with color-indicating desiccant (Drierite, Xenia, 
OH) and protected from light until insertion. 
 
6.2.3 Immunization studies 
 
 The immune response to microneedle delivery of measles vaccine was testing in 
rhesus macaques (Macaca mulatta). The animals were divided into groups of 4 monkeys 
each as follows: (1) full-dose delivered by subcutaneous injection and (2) full-dose 
delivered by dissolving microneedle patch. 
 Female, 2 year old rhesus macaques were kept in quarantine for 4 weeks and 
tested for antibodies to measles, influenza, polio and canine distemper virus. One week 
before the first vacation, blood was collected from a leg vein using Vacutainer tubes (BD, 
Franklin Lake, NJ). Animals were anesthetized by anim l facility staff using ketamine 
during vaccination and blood collection. For the microneedle vaccination group, a section 
of hair on the upper back of the animal was removed using electric shears followed by an 
application of depilatory cream (Nair, Princeton, NJ). 
 For the microneedle group, a single dissolving patch containing roughly 3500 
TCID50 infectivity units of measles vaccine was pressed into the skin at the site of hair 
removal. The patch was left on the skin for 10 minutes to ensure complete dissolution of 
the polymer needles. In the groups receiving a subcutaneous injection, the stock vaccine 
solution was diluted using sterile phosphate-buffered saline so that the target dose was 
containing in 500 µL. This solution was then injected subcutaneously using a 25-gauge 
needle into the back of the animal. The upper back was chosen for all vaccinations to 
prevent the animals from scratching the site and causing irritation. 
 Following vaccination, no adverse effects were noted after microneedle insertion 
or subcutaneous injection. After microneedle patch removal, a small grid of puncture 
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sites was faintly visible and some redness existed where the edges of the patch pressed 
into the skin. No bleeding was observed for any of the vaccinations. The microneedle 
insertion site was examined daily by animal care staff and no adverse effects were seen. 
The grid of puncture sites was no longer visible 2-3 days after insertion and no swelling, 
discharge or other abnormalities were observed at any point during the study. 
 Eleven weeks after the initial measles vaccinations, the animals in this study were 
subsequently given the inactivated polio and inactiv ted influenza vaccines. Due to their 
inactivated and non-adjuvanted nature we do not believe the subsequent vaccinations had 
any impact on measured measles antibody titers. 
 Once a week approximately 10 mL of blood was removed from a leg vein on each 
animal. Following the completion of the study, all nimals were transferred to other 
protocols within the CDC. The protocol for the rhesus macaque study was approved by 
the Animal Care and Use Committees of the CDC and the Georgia Institute of 
Technology. 
 
6.2.4 Neutralizing antibody measurements 
 
 Measles neutralizing antibody titers were measured f om collected sera using 
methods previously described [121]. In this study, two-fold dilutions of serum were 
tested starting at a dilution of 1:4. 
 
6.2.5 IgG and IgM ELISA measurements 
 
 A commercially available, indirect enzyme-linked immunosorbent IgG assay 
(Measles IgG ELISA II, Wampole Laboratories, Cranbury, NJ) and an IgM assay 
developed at the Centers for Disease Control and Prevention (CDC, Atlanta, GA) were 
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used for the detection and qualitative determinatio of IgG and IgM antibodies to measles 
virus in serum specimens. Positive, equivocal, and negative status of sera was determined 
using the cut-offs specified by the manufacturer based on index standard ratio (ISR) 
values. Seronegativity was defined as a serum ISR value of ≤0.90; sera with ISR values 
of 0.91–1.09 were considered equivocal and sera with ISR values of ≥1.10 were defined 
seropositive. 
 
6.2.6 Stability studies 
 
 In order to test the stability of the microneedle patches used in this study samples 
were stored at multiple temperatures for up to two m nths. Dissolving microneedle 
patches containing 4.5 log(TCID50) infectivity units of measles vaccine were created 
using the method described above. The titer in eachp tch was increased over the patches 
used in the immunization experiments to create a higher ceiling for the eventual detection 
of titer loss. After lyophilization, all patches were stored with color-indicating desiccant 
in an opaque pouch. The pouches were sealed twice us ng an industrial grade heat sealer 
(AIE-300, American International Electric, Inc., City of Industry, CA) to ensure that no 
moisture could penetrate the sample. Each sample was stored in duplicate at 4oC, 22oC 
and 40oC for 1 week, 1 month and 2 months. After the completion of storage, the sample 
pouches were opened and the titer was measured using a TCID50 assay. The color-
indicating desiccant was inspected for each sample. If evidence of moisture 
contamination was present the sample was discarded. All infectivity results were 






 All statistics for this study were calculated using Prism software version 6.02 
(Graphpad, La Jolla, CA). Comparisons between indivdual samples were done using an 
unpaired t-test was a significance cutoff of p<0.05. Comparisons between multiple 
samples was done using a two-way ANOVA with a Tukey post-test. Averages of 
log(TCID50) results represent the geometric mean of the samples. All other averages 
represent the arithmetic mean of the samples. 
 
6.3 Results 
6.3.1 Formulation of microneedles 
 
Figure 15: Dissolving microneedle patch containing measles vaccine. 
The microneedle patch was made predominately of a PVA and sucrose mixture. 
Each patch contained 100 pyramidal needles. The insert shows a single dissolving 
needle at high magnification. 
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 The needles used in this study were designed to enabl  simple skin insertion, 
rapid, complete dissolution in the skin and scalability to meet the needs of a global 
vaccination campaign.  
 Skin insertion of microneedles is known to depend o  sharpness of the needle tip 
[100]. After removal from the polymer mold, microneedle patches were examined under 
high magnification (Figure 15). Tip sharpness was determined to be less than 5 µm.  
 Needle dissolution was tested by inserting fully made needles into pig skin and 
leaving them for different amounts of time. Typical needles after 1, 5 and 10 minutes of 
insertion are shown in Figure 16. The tips of the ne dle dissolved almost instantly upon 
insertion in the skin with the top third of the needle gone after only 1 minute. Longer 
insertion resulted in dissolution of a majority of the needle shaft after 5 minutes while the 
remainder of the needle base was gone after 10 minutes. 
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 The needle casting process was designed to be simple and efficient. The 
fabrication process itself utilized a custom vaccine system which was designed to scale 
easily depending on the number of patches required. The system is simple and requires 
only a vacuum source to make sharp, strong patches. Since vaccine wastage is a major 
concern the addition of the vaccine solution and polymer matrix were split into separate 
steps ensure that nearly all of the measles vaccine would be concentrated in the needle 
Figure 16: Microneedle dissolution after insertion into pig skin. 
Dissolving microneedle patches were inserted into pig skin for 0, 1, 5 and 10 
minutes. The patches were then removed and examined at high magnification. After 




rather than the backing of the patch. This was confirmed by measuring the vaccine 
content before and after insertion into the monkeys. Prior to insertion, each patch 
contained approximately 3.5 log(TCID50) of live-attenuated measles vaccine. After 
removal from the skin the remaining polymer was tested for measles infectivity. We 
found that more than 90% of the dose in the patch was delivered into the animal after a 




6.3.2 Immunogenicity of the microneedle patch 
 
 The immune response following dissolving microneedl  patch delivery of the 
measles vaccine was evaluated in a non-human primate odel. The rhesus macaque is an 
extremely well-studied model for measles vaccination studies [130]. Rhesus macaques 
have previously been used to evaluate vaccine immunogenicity and have a strong 
Figure 17: Measles vaccine delivery efficiency using a microneedle patch. 
Dissolving microneedle patches containing measles vaccine were tested for viral 
infectivity using a TCID50 assay before and after insertion into the skin of a rhesus 
macaque. The patches were inserted for 10 minutes. The data presents the average 
(N = 3) ± SD. 
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correlation to humans with regard to immune response [50]. In this study, one group of 
monkeys (n = 4) received a full human dose (~3500 TCID50) of the live-attenuated 
measles vaccine via a dissolving microneedle patch nd the other group (n = 4) served as 
a positive control and received the same dose of vaccine via subcutaneous injection using 
a needle and syringe. A third group of rhesus macaques received the same dose of 
measles vaccine delivered using a metal microneedle to confirm the results obtained in 
the previously conducted cotton rat experiment [122]. Serologic testing during pre-
vaccination quarantine confirmed that the animals did not have existing neutralizing 
antibodies to measles or canine distemper virus. 
 
  
Figure 18: Measles neutralizing antibody titers following vaccination. 
Neutralizing titers were obtained from rhesus macaque sera using the method 
described earlier. Samples were tested weekly. The arrow indicates the date that a 
100% dose of monovalent measles vaccine was delivered to all animals 
subcutaneously. The neutralizing titers between the two groups were not statistically 
different except at day 139. The asterisk (**) represents a significant difference 
(p<0.005) as measured by ANOVA. The data points represent the average titer (N =
4) ± SD. The dashed line represents 200 mIU/ml which is generally recognized as the 
minimum titer required for protection. 
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 Serum samples were obtained weekly and tested for antibodies to measles virus. 
Neutralizing antibodies were detected at low titers beginning 21 days post vaccination 
and increased to a peak on day 28 (Figure 18). The time to peak titer was not significantly 
different between the two groups. Peak titers were not significantly different between the 
two groups indicating a potent immune response bothfr m the subcutaneous injection 
and the microneedle patch. After 133 days all animals were given a measles boost 
consisting of 1000 TCID50 of a licensed, monovalent formulation of measles vaccination 
via subcutaneous injection. One week after the boost, all animals showed an increase in 
titer. The average titer following the boost was stati ically higher for the subcutaneous 
group compared to the microneedle patch group (p<0.005)  Later time points did not 
show this statistical significance between groups but the data was confounded by the 
application of an MMR shot 1 week after the measles-only boost. All animals which 
received a measles vaccination using a coated, metal icroneedle displayed neutralizing 
titers which followed a similar curve as compared to the other tested delivery routes. 
However, these animals displayed statistically lower titers when compared to the 
subcutaneous control on days 28, 42 and 133 following vaccination (Figure 30). All 
animals in this group also demonstrated a marked increase in titer after the boost. 
 We tested for the presence of systemic IgG using a type-specific ELISA. As 
expected, serum IgG antibodies were detected in all animals (Figure 19) indicating that 
all animals had a robust immune response following vaccination. A general rise in IgG 
titer was detected in both groups which peaked at day 21. We did not detect any 
correlation between IgG OD values and plaque neutralizing antibody titers. The 
difference in IgG ELISA OD values in the two vaccinated groups were not statistically 
significant at any time point. 
 Serum IgM levels were also detected using a measles-sp cific ELISA (Figure 20). 
During the immune response to vaccination, IgM levels typically precede the appearance 
of IgG [144]. The presence or absence of these antibodies is often used as a first detection 
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method to ensure a vaccination has activated the immune system. Measles specific IgM 
was detected for every animal in both groups indicating generation of a primary immune 
response to measles vaccine. In both groups the IgM ELISA OD values rose to a peak by 
day 14 then quickly receded. All animals had positive IgM levels by 21 days following 
vaccination. 
 Vaccination using dissolving microneedles resulted in a lower day 14 OD value 
when compared to the subcutaneous vaccination group. This difference was statistically 
significant (p<0.0005). The difference remained signif cant on day 21 (p<.005) but was 
no longer significant on day 28. Measles IgM ELISA OD values have not been shown to 
correlate with eventual neutralizing titer values. While the lower values produced by the 
dissolving microneedle group was unexpected it did not result in lower neutralizing titers 
at any point after the vaccination.  
 
Figure 19: Serum IgG levels as measured by ELISA. 
Sera was tested weekly for the first 28 days following vaccination for the presence of 






 The microneedle patches were well tolerated in all animals with no adverse 
effects seen by the investigators or animal care staff. Following removal of the patch, 
some mild redness was present around the site of insert on. One week after patch removal 
the redness had dissipated and the microneedle insertion site was indistinguishable from 
other shaved portions of the animal (Figure 21). The veterinary staff reported no study-
related health problems in the animals and no irritation or evidence of discomfort was 
seen in any animal at the application site. 
 
 
Figure 20: Serum IgM levels as measured by ELISA. 
Sera was tested weekly for the first 28 days following vaccination for the presence of 
measles-specific IgM. The asterisk (**** or **) represents a significant difference 
(p<0.00005 or p<0.005 respectively) as measured by ANOVA. The bars represent 




6.3.4 Microneedle patch stability 
 
 Complete microneedle patches containing a high dose of measles vaccine were 
stored at multiple temperatures to examine their stabili y over time. Previous studies have 
shown that the addition of excipients have the potential to significantly increase the 
Figure 21: Rhesus macaque skin before and after microneedle patch insertion. 
The pictures represent the same area of skin at different time points before and 
after microneedle patch insertion. A: After hair removal and immediately before 
insertion. B: After insertion of the patch. C: Immediately after patch removal. D: 1 
week after patch removal. 
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ability of the dried measles vaccines to retain activity over time [92, 122]. This was the 
first study to examine the stability of measles vaccine which had been encapsulated in 
dissolving microneedle patches.  
 Though there was some variability in the early data, microneedle patches 
containing both measles vaccine and stabilizing excipients retained complete infectivity 
as measured by TCID50 after 2 months of storage at both 4oC and 22oC (Figure 22). There 
was no detected loss in either of the samples at the end of the study. The lower infectivity 
titers at early time points could be the result of variability between microneedles or could 
Figure 22: Stability of measles virus after micronedle creation and storage. 
Microneedle patches were created which encapsulated measles vaccine. The vaccine 
was mixed with the stabilizers sucrose and threonine during needle processing as 
indicated in Section 6.2.2.2. The patches were stored for the number of days 
indicated at 3 different temperatures and then tested for viral inf ectivity using a 
TCID 50 assay. Humidity was controlled using a color-indicating desiccant. The data 
points represent the average (N = 2) ± SD. The dashed line represents the range 








have been caused by the inherent error present in the TCID50 assay. 
 The infectivity loss at the higher temperature was more pronounced. The 
microneedle patch lost 32% of its infectivity after he first week of storage. At the end of 
2 months the encapsulated vaccine retained, on average, approximately 10% of its 
original potency. The data from this study was compared to the stability results obtained 
from the eGFP-MeV assay used in Chapter 5 (Section 5.2.3). We found that the average 
activity at the elevated temperature condition was similar at the 1 month and 2 month 
time points for both the eGFP and traditional TCID50 assays (Figure 23). As expected, the 
standard deviation for the TCID50 assay was much larger. 
 
 
Figure 23: Stability after drying as measured by two different assays. 
The activity of the measles virus after drying and storage was measured 
independently using multiple assays. For the eGFP-MeV test, a small amount of 
eGFP measles vaccine was placed on a metal chip and dried as indicated in Section 
5.2.3. This sample was stored at 45oC for the time indicated and the fluorescence 
was compared to a liquid sample of eGFP-MeV. For the MN patch test, the samples 
were created and stored at 40oC as indicated in Section 6.2.6 These patches were 
tested for activity using a TCID50 assay and the infectivity was compared to a 
control MN patch. The bars represent the average (N = 3 or 2 for the eGFP-MeV 




 The current method of delivering the measles vaccine, subcutaneous injection, has 
a number of logistical drawbacks. These include the requirement for trained personnel at 
the time of delivery, dangers associated with sharps disposal and the inefficiency caused 
by vaccine wastage. Any new vaccine delivery method must also generate a potent 
immune response following delivery. Dissolvable microneedle patches have the potential 
to mitigate many of these problems and help advance the current measles elimination 
goals.  
 The creation of a dissolving microneedle patch that met these requirements was a 
significant advancement. A patch that was difficult to insert into the skin or did not 
deliver a full dose of measles vaccine would be insufficient to address the hurdles which 
are impeding the measles elimination program. Previous work in our lab has shown that 
microneedle patches consisting of 100 needles was able to insert into the skin with as 
little as 3 N of force [100]. This is comparable to pushing a button on an elevator. This 
would represent a significant simplification of the current injection-based delivery 
method for measles vaccine. Our needles were proven to be both sharp enough to enable 
easy insertion while simultaneously having the strength necessary to withstand this force 
without fracturing. Our dissolving microneedle patch requires no additional applicator 
and we envision a system as simple as applying an adhesive bandage as the final product. 
By removing the requirement for trained medical personnel, microneedles could allow for 
door to door measles immunizations. This has the pot ntial to significantly increase the 
scope of mass vaccination campaigns, helping to accmplish the goal of greater than 95% 
vaccine coverage in the third world. 
 Dissolvable needles, such as those used in this study, also eliminate the risk posed 
by medical sharps waste. Following insertion, the ne dles on our patch were shown to 
completely dissolve in the skin. No needle tips remained on the patch after removal. Used 
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microneedle patches have no potential for reuse, further increasing the safety of mass 
vaccination campaigns. Additionally, the disposal of n n-sharps medical waste requires 
fewer precautions and has a lower cost than the disposal required for used needles. We 
imagine the disposal of microneedle patches to entail a similar burden as disposing used 
bandages. 
 Vaccine spoilage due to improper handling and temperature conditions remains a 
significant contributor to campaign costs [95]. Our microneedle patch represents a new 
mechanism for delivering single vaccine doses which requires no prior modification or 
reconstitution. The elimination of the reconstitution buffer removes a possible source of 
handling error which can result in wasted vaccine. The simplification provided by a 
single contained dosing system would also lower transport and storage costs, which also 
has the potential to expand the scope of mass vaccination efforts. Our work has shown 
that encapsulation of the measles vaccine in a microneedle patch can result in lowered 
loss at elevated temperatures. Current measles vaccine standards require that after 
reconstitution all doses must be delivered in 6 hours to minimize spoilage. Our patches 
maintained complete infectivity in both refrigerated and ambient conditions for 2 months. 
Additionally, at elevated temperatures we found that our patch could last for 2 months 
before losing 1 log(TCID50) unit of infectivity. Other studies involving more complicated 
drying methods showed similar results after storage at levated temperatures [92]. While 
the loss in potency at elevated temperatures was significant it still represented a major 
improvement from our previous work. That study showed that dried vaccine stored at 
37oC lost more than 2.5 log units after only a month [122]. This advancement could allow 
for the possibility of short-term removal of measles vaccine patches from the cold chain 
during delivery. This would be hugely beneficial as vaccine campaigns moved from 
major population centers into less developed regions. This would represent a major step 
towards a safer, cheaper, more effective vaccine delivery system. 
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 We also showed that our microneedle patch was effective and generated a potent 
immune response after insertion. This response was assessed in rhesus macaques, a well-
established, non-human primate model for measles [50]. Previous studies in our lab found 
that measles delivered using a microneedle was immunogenic and non-inferior to syringe 
delivery in the cotton rat model [122]. However, microneedle vaccination has never been 
assessed in a non-human primate model. Rhesus macaques re a well-studied model for 
measles and produce a robust, easily quantified immune response to both wild-type and 
live-attenuated virus [130]. For this study, slightly more than a full human dose (~3000 
TCID50) of measles virus was delivered either subcutaneously or into the skin using a 
microneedle patch. Both groups had neutralizing antibody levels that were significantly 
higher than the 200 mUI/ml level that is generally regarded as the minimum titer need for 
protection. The antibody titers were not statistically different between the two vaccination 
groups. Titers decreased slightly over time, but remained well above the threshold of 
protection for over 4 months following a single vaccination. We also tested for systemic 
serum IgG and IgM levels using an ELISA. Though IgM OD levels were found to be 
statistically lower in the microneedle group these titers have not been shown to correlate 
with eventual neutralizing antibody levels. We did show that all animals had a positive 
IgM response by day 21 which is an important initial m rker of vaccine efficacy. IgG OD 
levels were not found to be significantly different between the groups and all animals had 
a potent response following vaccination. Therefore, ur microneedles have the ability to 
insert into the skin and dissolve, allowing the released vaccine to reconstitute in vivo and 







 This study examined for the first time the immune response in rhesus macaques to 
measles vaccine delivered using a novel microneedle patch created using a safe, bio-
absorbable polymeric compound. These needles were shown to be sharp, strong and able 
to successfully penetrate the skin to deliver a standard dose of measles vaccine. In 
addition, the process used to fabricate these patches is simple, and scalable to the extent 
required by global measles elimination efforts. This work shows that microneedles are a 
suitable carrier for the measles vaccine and represnt a solution to many of the problems 
that currently face measles mass vaccination programs. We believe measles vaccine 
delivery using microneedle patches has the potential to greatly aid the measles 
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CHAPTER 7  Inactivated polio vaccination using a dissolving 




 Due in large part to the efforts of the WHO and the Global Polio Eradication 
campaign, worldwide confirmed polio cases have reach d their lowest level in history 
[5]. The current target for the total eradication of the disease is fast approaching [145]. In 
the quest to reach this outcome, significant financial resources in conjunction with an 
extremely effective vaccine are crucial. Poliomyelitis s caused from an infection by one 
of 3 serotypes of poliovirus. Each serotype contains different capsid proteins which 
dictate cellular receptor specificity and viral antigenicity [146]. Since protection from one 
strain does not protect against the others, most polio vaccines contain antigens for all 
three serotypes to confer complete protection from the disease. Of the two vaccine types, 
the oral polio vaccine (OPV) is the easiest to deliver, extremely inexpensive to produce 
and has a high immunological efficacy [107]. Unfortunately, due to its nature as a live-
attenuated vaccine, OPV carries with it an ability to revert back to its virulent, wild-type 
form which can result in the transmission of vaccine-derived polio viruses [108]. The 
WHO has recommended that as polio eradication progresses, countries should begin to 
transition from OPV to the inactivated polio vaccine (IPV) [110]. The inactivated polio 
vaccine does not have any risk of reversion, making it more suitable to a world without 
poliomyelitis. IPV is currently delivered using a standard needle and syringe injection 
which presents many problems in a mass vaccination setting. Intramuscular injections 
require trained personnel to ensure proper vaccine delivery, vaccine spoilage can lead to 
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significant product wastage and the disposal of medical sharps constitutes a significant 
burden for large-scale campaigns. 
 The requirement for trained personnel to deliver IPV is a significant barrier to its 
wide use in third-world campaign settings. The door t  door delivery of OPV is a major 
factor in the resulting high vaccination rates [147]. Alternative delivery methods which 
could simplify vaccine administration have the potential to significantly decrease the cost 
of adapting IPV to the existing OPV framework. Additionally, IPV is traditionally 
delivered using multidose vials. The number of undelivered doses which are wasted 
varies significantly from campaign to campaign and can result in the wastage of a 
nontrivial portion of the potential vaccine stock [148]. Mitigating this wastage would 
allow for a higher percentage of the purchased vaccine to make it into patients. Finally, 
transport, storage and eventually disposal of the resulting medical waste presents a 
problem for large-scale vaccination campaigns [63]. This burden is in addition to the 
increased risk of needle reuse and misuse created by delivery using syringe injection. 
Removing the risk of sharps and lessening the burden of medical waste disposal from 
delivery of IPV would be a major benefit to the global polio eradication campaign. A 
promising technology with the ability to achieve targeted skin delivery is the microneedle 
patch. 
 Microneedles are small, micron-scale needles which penetrate the skin and have 
the potential to deliver biologics to the upper layers of the skin in a targeted manner [12]. 
Microneedles have previously been used to delivery other vaccines such as measles, 
influenza and BCG [111, 115, 122]. Delivery to skin of these vaccines has resulted in 
either equivalent or enhanced immune response when compared to delivery using a 
traditional needle and syringe. Microneedle patches ar  also simple to insert and require 
minimal training to achieve a successful delivery. This would remove the burden of 
trained delivery and allow for a better allocation f scarce personnel resources. 
Microneedle patches can also be fabricated out of bio-adsorbable polymers [2]. After 
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insertion into the skin, the needles are removed along with the vaccine leaving a patch 
without the risk posed by contaminated sharps. This reduces the risk to both the 
vaccinator and patient. Additionally, the patches can then be simply disposed in a manner 
similar to used bandage. Finally, microneedle patches would require a lower cost to ship 
and store as a result of their small size and integra d design. Microneedle patches could 
be designed to contain a single dose of IPV in a compact package that required no 
secondary support materials. Rather than transporting needles, syringes and vials 
independently, a single microneedle patch could incorporate everything needed to deliver 
the vaccine. 
 This study, for the first time, examines the immune response to delivery of IPV in 
the skin using a microneedle patch. Dissolving microneedle patches containing a full 
human dose (40, 8, 32 D-antigen units of IPV type 1, 2 and 3 respectively) were inserted 
into the skin rhesus macaques. This delivery system was compared to the same dose of 
IPV delivered using an intramuscular injection utilizing a standard needle and syringe.  
 
7.2 Materials and methods 
7.2.1 Concentration of inactivated polio vaccine 
 
 Unformulated, monovalent, bulk inactivated polio vaccine was kindly provided 
by GlaxoSmithKline Biologicals (Rixensart, Belgium). The starting antigen concentration 
was measured to be 2023, 831, 1081 D-antigen units of IPV type 1, 2 and 3 respectively. 
Concentration of the bulk IPV was done using Amicon Ultra centrifuge spin filters with a 
100kDa molecular weight cutoff (Merck, Whitehouse Station, NJ). The stock IPV was 
concentrated approximately 38x by volume and the final antigen concentration was 
measured to be 56,300, 39,500, and 52,300 D-antigen/mL for type 1, 2 and 3 
respectively. All D-antigen values were determined by ELISA. 
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7.2.2 Microneedle fabrication 
7.2.2.1 Inactivated polio vaccine filling 
 
 Molds consisting of a 10 x 10 array of 300 x 300 x 600 µM pyramidal 
microneedles with a tip-to-tip spacing of 640 µM were fabricated as previously described 
[142, 143]. Polio vaccine solution was concentrated as described above. This 
concentrated stock was added in a 1:1 ratio to a solution consisting of 15% w/v sucrose 
(Sigma-Aldrich, St. Louis, MO) and 300 mM threonine (Sigma-Aldrich). This solution 
was mixed and applied to the microneedle mold. The solution was evenly spread over the 
entire mold surface using a pipet tip. This mold was then placed in a custom-made 
vacuum system and suction was pulled through the bottom of the mold at a pressure of 
approximately -3.59 kPa for 20 minutes. The mold was removed from the vacuum system 
and allowed to dry in a fume hood for 60 minutes. Adhesive tape (Sigma-Aldrich) was 
applied to the dried mold. This tape was then quickly peeled away to remove any 
remaining vaccine solution present on the mold. 
 
7.2.2.2 Polymer matrix filling 
 
 The backing matrix for the dissolving microneedles was composed of a 40 wt% 
solution of fish gelatin (Sigma-Aldrich) and 15 wt% sucrose (Sigma-Aldrich) in DI-H2O. 
The fish gelatin solution was mixed for 1 hour at 25°C before use. The backing matrix 
material was spread using a spatula over the tape-stri ped microneedle mold. The molds 
were placed back into the vacuum system and suction was applied at a pressure of 
approximately -3.59 kPa for 90 minutes. The molds were then allowed to dry for 48 
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hours at 25°C in a fume hood. To remove the needle patches a circle of dextrin (Sigma-
Aldrich) was coated with double-sided tape (MacTac, Stow, OH) and applied to the back 
of the mold. This disc was gently peeled away from the mold taking care to prevent 
damage to the needles. Patches were stored in a light-protected, sealed pouch with color-
indicating desiccant (Drierite, Xenia, OH) until insertion. 
 
7.2.3 Immunization studies 
 
 The immune response to microneedle delivery of inact v ted polio vaccine was 
tested in the rhesus macaque (Macaca mulatta). The animals were divided into groups of 
4 monkeys each as follows: (1) full-dose delivered by intramuscular injection and (2) 
full-dose delivered by microneedle patch. 
 Female, 2 year old rhesus macaques were kept in quarantine for 4 weeks and 
tested for antibodies to measles, influenza, and canine distemper virus. In order to 
determine that the animal had no previous exposure to polio, blood was collected from a 
leg vein using Vacutainer tubes and analyzed by plaque micro-neutralization (BD, 
Franklin Lake, NJ). Animals were anesthetized by anim l facility staff using ketamine 
during vaccination and blood collection. For the microneedle vaccination group, a section 
of hair on the upper back of the animal was removed using electric shears followed by an 
application of depilatory cream (Nair, Princeton, NJ). 
 After characterizing the dose in each patch, 4 monovalent dissolving patches (2 
IPV type 1 patches and 1 patch of type 2 and type 3) containing a total of 47.4, 8.2, 38.2 
D-antigen units of IPV type 1, 2 and 3 respectively were pressed into the back, between 
the shoulder blades, of the each animal. This site was chosen to prevent the animals from 
scratching the site and causing irritation. The patches were left on the skin for 15 minutes 
to ensure complete dissolution of the polymer needles. In the groups receiving an 
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intramuscular injection, the un-concentrated GSK stock solution was diluted using sterile 
phosphate-buffered saline so that the target dose (40, 8 and 32 D-antigen units of type 1, 
2 and 3 respectively) was contained in 500 µL. The intramuscular injection was delivered 
in a single trivalent preparation using a 25-gauge ne dle into the thigh muscle of the 
animal.  
 Eight weeks after the initial vaccination all animals were given a 2nd dose of IPV. 
The booster dose was delivered using the same route as the initial vaccination and 
consisted of the same dose of IPV. 
 Once a week approximately 10 mL of blood was removed from a leg vein on each 
animal. Following the completion of the study all animals were transferred to other 
protocols within the CDC. The protocol for the rhesus macaque study was approved by 
the Animal Care and Use Committees of the Centers for Disease Control and Prevention 
and the Georgia Institute of Technology. 
 
7.2.4 Neutralizing antibody measurements 
 
 Neutralizing antibody titers to poliomyelitis were measured from collected sera 
using methods previously described [149]. In this study, two-fold dilutions of serum were 
tested starting at a dilution of 1:4. 
 
7.2.5 Enzyme-link immunosorbant assay 
 
 Antibody-capture ELISA was used for the detection of D-antigen poliovirus. 
Poliovirus-specific monoclonal antibodies (mAb) were used as both capture and detection 
antibodies. Type 1 (NBP1-05101, Novus Biologicals, St. Louis, MO) type 2 (HYB294-
06, Thermo Fisher Scientific, Waltham, MA), or type 3 (HYB300-05, Thermo Fisher 
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Scientific) specific antibodies were diluted in 0.05M carbonate-bicarbonate buffer, pH 
9.6. Type 1, 2 and non-D-antigen type 3 capture mAb were diluted 1:1000. For the D-
antigen specific type 3 ELISA the capture antibody (HYB300-06, Thermo Fisher 
Scientific) was diluted 1:500. Fifty microliters of diluted antibody was dispensed into 
Immulon 2HB high-binding 96-well plates (NUNC, Inc., Penfield, NY) which were 
incubated for a minimum of 16 hours or up to 7 days t 4°C in a moist chamber. The 
antibody-coated plates were washed four times in wash buffer (0.01 M PBS, pH 7.2 with 
0.05% Tween 20), followed by blocking with 100 µl of dilution buffer (0.01 M PBS, pH 
7.2 with 0.5% gelatin and 0.25% Tween 20) for 60 min at 37°C in a humid chamber.  The 
plates were then washed four times with wash buffer and 50 µl of was added to each well 
of the antibody-coated plates and incubated for 60 min at 37°C in a moist chamber.  For 
detection, horseradish peroxidase labelled (HRP) poliovirus type-specific monoclonal 
antibodies were prepared with a Lightning Link Conjugation kit (HRP, 1 x 100 µg 
reaction) (Novus Biologicals). All HRP-conjugated antibodies were diluted at 1:1000 in 
dilution buffer.  The plates were washed four times in wash buffer and 50 µl of diluted 
serotype-specific HRP-labelled mAb was added to each well. The plates were incubated 
for 60 minutes at 37°C in a moist chamber, washed four times with wash buffer, and 50 
µl of SureBlue Reserve TMB Microwell Peroxidase Substrate (1-Component) (KPL, 
Gaithersburg, MD) was added to each well. The plates were incubated at room 
temperature for 15 minutes and the reaction was stopped by addition of 50 µl of TMB 
BlueSTOP Solution (KPL).  Plates were then evaluated on a plate spectrophotometer at a 





 All statistics for this study were calculated using Prism software version 6.02 
(Graphpad, La Jolla, CA). Comparisons between indivdual samples were done using an 
unpaired t-test was a significance cutoff of p<0.05. Comparisons between multiple 
samples was done using a two-way ANOVA with a Tukey post-test. 
 
7.3 Results 
7.3.1 Microneedle patch testing 
 
 The patches created during the course of this study were designed to be simple to 
manufacturer, easy to insert and able to contain a full dose of the inactivated polio 
vaccine. Using a vacuum filling system, dissolving microneedle patches were molded out 
of a fish gelatin and sucrose solution. The resulting patches contained a 10 x 10 array of 
pyramidal needles which were approximately 650 µm in height (Figure 24). These 
patches were first tested to ensure they possessed both the strength to successfully insert 
into the skin and the correct dose of inactivated polio vaccine. Needle strength was 
assessed by inserting fully-made patches into pig skin and examining the ability of the 
needles to pierce the skin. This method has been prviously used to test needle strength 
[24]. Upon insertion into the skin, small holes arec ated in the stratum corneum. These 
holes can be detected with the application of a dye. Microneedle patches were inserted 
into pig skin for 15 minutes and then examined under magnification. After staining, an 
insertion success rate of 100% was calculated by counting the detected holes and 
comparing it to the 100 needles on the microneedle patch (Figure 25). Subsequent testing 
was done to ensure that the needle fully dissolved after insertion. After 15 minutes of 
insertion into pig skin the vast majority of both the needle shaft and needle base were 
dissolved (Figure 27). This test confirmed that the microneedle patches created for this 
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Figure 24: Microneedle patch containing IPV at high magnification. 
Dissolving microneedle patches were created out of fish gelatin using a vacuum 
filling process. The needles were approximately 650 µm in height. A 10 x 10 array is 
shown. The insert shows a single needle from this arr y at high magnification. 
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Figure 25: Pig skin after microneedle patch insertion and staining. 
A single microneedle patch was inserted into excised and shaved pig skin. The patch 
was removed after 15 minutes of insertion. The skin was then stained to show the 
puncture sites. 
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 The needles were then assayed for their IPV content usi g a serotype-specific 
ELISA. Initial testing found that each monovalent pa ch contained an average of 23.7, 8.7 
and 38.2 D-antigen units of IPV type 1, 2 and 3 respectively. After the completion of the 
study it was found that the antibody in the ELISA used to measure the dose of IPV type 3 
was not specific for the D-antigen conformation of the antigen. Testing was done to 
compare type 3 patches on both the old and a new ELISA which utilized a D-antigen 
specific antibody. It was found that the delivered D-antigen dose for type 3 was 
approximately 66% lower than expected (p<0.05) (Figure 26). 
Figure 26: IPV 3 dose tested with multiple ELISAs. 
The D-antigen amount loaded into multiple microneedle patches was assayed using 
two different ELISA tests. The original ELISA utili zed an antibody that was not 
specific for the D-antigen region of IPV type 3 while the new ELISA used a different 
ELISA that had this specificity. The results show that after needle creation, much 
less of the IPV type 3 retains the D-antigen conformation than originally estimated. 
Each bar represents the average (N = 3) of individually tested patches. The asterisk 
(*) denotes a significant difference (p<0.05) as measured by an un-paired t-test. 
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Figure 27: Microneedle patch before and after insertion into pig skin. 
Microneedle patches were created and then inserted into pig skin to determine the 
dissolution time. From top to bottom, this figure shows microneedles at high 
magnification 0, 1, 5 and 15 minutes after insertion and removal. 
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7.3.2 Immunization Study 
 
 The rhesus macaque was chosen for this study becaus  it has historically been 
used to test inactivated polio vaccine efficacy and viral potency [150]. Prior to 
vaccination, each animal was tested for pre-existing, neutralizing antibodies to each polio 
serotype. For this study two groups were used. The first group (n = 4) received at least a 
full human dose of IPV type 1 and 2 (47.4, 8.7 D-antigen units) delivered using a 
dissolving microneedle patch. These animals only receiv d approximately 13.06 D-
antigen units of type 3 as a result of incorrect initial ELISA information. The second 
group (n = 4) received a full human dose delivered intramuscularly using a needle and 
syringe. The animals were bled weekly and the sera were tested for neutralizing 
antibodies using the gold-standard micro-neutralization assay [151]. For polio serotype 1, 
75% of the animals which received a dissolving patch had a positive titer (≥ 3.0 log2 
units) by 8 weeks after vaccination while the IM injection group displayed 50% 
seropositivity. The average titer for the dissolving microneedle and IM injection groups 
at this time point was 3.9 and 4.3 respectively. All animals exhibited higher antibody 
titers to a single dose of IPV type 2 when compared to the other IPV serotypes. The 
enhanced immunogenicity of IPV type 2 after a single polio immunization has also been 
seen in vaccination studies done in children [152]. For type 2, the seropositivity at 8 
weeks was 100% for both groups while the average titer was 5.5 and 6.3 for the 
microneedle and IM groups respectively. The immunologic response to IPV type 3 was 
the weakest amongst the three serotypes. No animals n either group were seropositive at 





 The low titers observed at 8 weeks post-vaccinatio for IPV type 1 and type 3 
necessitated the need for a second vaccine dose, delivered 8 weeks after the initial 
vaccination. The booster dose also produced no adverse events. Following the second 
dose, almost all of the animals exhibited a priming response. The average log2 titer for 
IPV 1 peaked at 10.1 and 11.4 for the dissolving needle and intramuscular injection 
groups respectively. The average titer for IPV 2 peaked at 11.9 and 12.8 for the two 
groups. The neutralizing antibody responses were not significantly different between the 
two groups for IPV type 1 or 2 (p > 0.05). In addition, the average titer on each day was 
statistically similar for each group (p > 0.05). This indicates that the immune response to 
IPV type 1 and type 2 was indistinguishable when comparing microneedle delivery to an 
intramuscular injection. This was not the case for IPV type 3. Following the boost, the 
average titer for the intramuscular injection peaked at 9.3 while the peak titer for the 
dissolving needle group was 3.7. The average titers b tween the two groups were 
statistically different over time (p<0.005). This inferior response could be due to the low 
dose delivered for type 3 which was detected after th  completion of the study using a D-
antigen specific type 3 ELISA. Animals were also vaccinated using coated, metal 
microneedle patches. The response to this delivery route proceeded comparably to the 
other two groups. The neutralization titers were stati tically lower when compared to the 
subcutaneous control at a number of time points after the boost for all IPV serotypes 
(Figure 31). The final IPV type 3 seropositivity results were also lower in the metal 
microneedle group. 
 At the conclusion of the study, the seropositivity rates were 100%, 100%, 25% for 
the dissolving microneedle patch group and 100%, 100%, 75% for the group receiving an 
IM injection for types 1, 2, and 3 poliovirus respectively (Figure 28).  
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Figure 28: Neutralizing titers to IPV following vaccination. 
Sera was taken from rhesus macaques weekly following vaccination. Neutralizing 
titers were determined using a serotype-specific plaque micro-neutralization 
assay. We detected no significant difference in titer between the groups for IPV 
type 1 or 2. There was a difference between the groups for IPV type 3. Each data 
point represents the average (N = 4) ± SD. The asterisk (****) represents a 
significant difference (p<0.00005) as measured by ANOVA. Seropositivity was 




 Following either vaccination, no adverse effects were noted after microneedle 
insertion or intramuscular injection. After removal of the microneedle patches a small 
grid of puncture sites was faintly visible and minor redness existed where the edges of the 
patch pressed into the skin (Figure 29). The grid of puncture sites was no longer visible 
2-3 days after insertion. No bleeding was observed for any of the vaccinations. The 
vaccination sites were examined daily by animal care staff and no study-related adverse 
effects were seen. No swelling, discharge, irritation or other abnormalities were observed 
at any point during the study. 
 
Figure 29: Rhesus macaque skin during and after microneedle patch insertion. 
A 10 x 10 array of dissolving microneedles were inserted in the skin of the rhesus 
macaque between the shoulder blades after hair removal. These patches were 
removed after 15 minutes of insertion. The left image shows the patch in the skin. A 
grid can be seen where the needles have punctured the skin. The right image is the 
same area of skin immediately after patch removal. A faint grid can be seen which 





 The WHO has recommended that member countries begin transitioning to the 
inactivated version of them polio vaccine as eradiction progresses due to in large part 
because this vaccine has no danger of reverting to a virulent form. IPV is currently 
delivered using a needle and syringe which introduces a number of drawbacks when 
compared to the oral delivery route utilized by OPV. Syringe injection requires the 
presence of trained personnel and increases the risk of disease transmission due to needle 
reuse. The transition to IPV would be greatly aided by an improved method of delivering 
the inactivated polio vaccine [153]. 
 We have created a microneedle patch using a process that is simple, repeatable 
and importantly, scalable to the demands required by the polio eradication campaign. 
These patches can be inserted into the skin without the use of a secondary applicator, 
simplifying administration. Microneedle patches would also likely not require medically 
trained personnel to ensure proper insertion. This c ange would shift the vaccination 
scheme towards the more efficient method currently used with the oral polio vaccine. 
Dissolving microneedles in particular have the potential to eliminate the risk of sharps 
contamination since the needles no longer remain on the patch after insertion into the 
skin. Finally, a single-dose packaging system could decrease both shipping costs and 
medical waste, which are significant factors in large-scale vaccination campaigns. Our 
patches were tested in pig skin and found to easily insert with near-complete needle 
dissolution within 15 minutes. These are important qualifications for a delivery device 
intended to overcome many of the hurdles posed by the upcoming transition from OPV to 
IPV.  
 The microneedles patches were then inserted into the skin of a rhesus macaque 
and delivered at least a full human dose of inactivted polio vaccine types 1 and 2. The 
vaccine remained immunologically active and induced a potent neutralizing antibody 
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response after two doses. The serologic response to IPV type 1 and type 2 delivered using 
a microneedle patch was statistically indistinguishable from a similar dose delivered 
using a traditional needle and syringe. The positive response to IPV type 2 is especially 
important. The final stage of polio eradication calls for the administration of a bivalent 
oral vaccine protecting against polio type 1 and 3 with a supplementary dose of IPV type 
2 [110]. It is expected that this delivery schedule will continue throughout the final years 
of the eradication [154].  
 The immune response to IPV type 3 proved to be infrior when microneedle 
delivery was compared to an intramuscular injection. The D-antigen component of polio 
is thought to be the primary immunogenic region of the virus [155]. We hypothesize that 
this region of IPV type 3 was damaged during the creation of the microneedle patches. 
When comparing the results of our original type 3 ELISA to an improved type 3 ELISA 
based on a D-antigen specific antibody, testing showed that the delivered dose of IPV 
was much lower than predicted. We believe this was the primary factor which contributed 
to the lowered immune response. Further testing will be done to improve the needle 
creation process with the goal of minimizing antigenic loss for IPV type 3. 
 One alternative method that has been previously used to deliver IPV into the skin 
is the liquid jet injector [156]. Jet injectors are d vices which propel a liquid formulation 
of the vaccine at speeds high enough to penetrate str tum cornea, depositing their payload 
in the dermal or subcutaneous layers of the skin [119]. While suited to deliver many 
doses in rapid succession, care must be taken to prevent disease transmission due to 
nozzle contamination [120]. This problem has been largely solved through the use of 
disposal parts, though this would require a fresh applicator for each patient adding weight 
to both the initial shipment and eventual medical wste elimination. These devices are 
also not ideal for delivering vaccines in a door to door setting, limiting the potential reach 
of large-scale vaccination campaigns. We believe that microneedles have the potential to 





 Dissolvable microneedle patches represent a significa t advance over traditional 
delivery of the inactivated polio vaccine. They aresimple to administer, contain no risk 
of sharps and their small size has the potential to reduce the cost of vaccine storage and 
transport. This study showed that this alternative delivery method can induce a potent 
immunogenic response to skin delivery of IPV. More work needs to be done to optimize 
this new delivery platform. Future studies integrating all three serotypes into a single 
patch and work towards a Phase I clinical trial are ongoing. As the endgame nears for the 
global campaign to eliminate poliomyelitis, microneedles represent a possible solution to 
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CHAPTER 8  CONCLUSIONS  
 
 Microneedles have been shown to be an effective delivery vehicle for 
administration of the live-attenuated and inactivated polio vaccines. This project 
encompassed the development of microneedle patches for measles and polio vaccines 
from concept to a preclinical, non-human primate study. A summary of the relevant 
advances from each study are detailed below: 
 
8.1 Measles Vaccination in Cotton Rats using a Microneedle Patch 
 
 The goal of this study was to adapt the live-attenuated measles vaccine into 
currently existing metal microneedle patch technology. We have shown that the measles 
vaccine can be dried and stored for short time periods with acceptable levels of activity 
loss. This loss can be minimized with the addition of stabilizing excipients. We also 
showed that after delivery to the skin, microneedles produce a neutralizing antibody titer 
statistically equivalent to delivery using a standard subcutaneous injection. Specific 
advances are as follows: 
• The live-attenuated measles vaccine rapidly loses activity after drying. More than 
1.0 log(TCID50) units of infectivity loss was seen after 24 hours. 
• Infectivity loss can be mitigated by the addition of excipient compounds. While 
fish gelatin and malto-dextrin had minimal effect on stability, the sugar trehalose 
proved to be highly efficacious. 
• A combination of trehalose and protection from humidity resulted in a 
formulation that was stable for 30 days at 25oC. 
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• This formulation was less stable at elevated temperatures. A loss of more than 2.0 
log(TCID50) units was seen after 1 month of storage at 37oC. 
• Microneedle delivery of measles vaccine was shown to be equivalent to the same 
dose delivered using a subcutaneous injection. Peakn utralizing titers for the full 
dose of vaccine were 6.4 and 6.2 log2 units for the microneedle and injection 
groups respectively. 
• No dose sparing was seen after delivery of the measles vaccine to the skin. The 
titers for a 20% dose delivered using microneedles or a subcutaneous injection 
were equivalent. Peak titers for the 20% dose were 5.4 and 4.6 log2 units for the 
microneedle and injection groups respectively. 
 
8.2 Discovering Stabilizing Excipients for the Measles Vaccine using a High-
throughput eGFP assay 
 
 The goal of this study was to develop an assay which could rapidly screen 
excipients for their ability to stabilize the live-attenuated measles vaccine after drying and 
storage. We found the eGFP-MeV could be used in a 96-well plate assay to quickly and 
simply measure the activity of measles vaccine after storage at a variety of temperatures. 
This assay allowed us to screen a large number of excipi nts for their ability to stabilize 
the measles vaccine virus after drying. The results of his study are summarized below: 
• Measles vaccine virus encoding green fluorescent protein was used to develop an 
assay to rapidly assess viral infectivity. This significantly increased the 
throughput of infectivity testing over the standard TCID50 assay. 
• This assay was able to measure the infectivity of 96 separate samples of measles 
virus in less than 5 minutes and after only 3 days of incubation. 
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• This assay was used to test the stabilizing activity of more than 40 common 
commercial excipients. 
• It was determined that a combination of an amino acid and a sugar had 
significantly higher stabilizing activity than either compound individually. 
• The best formulation was determined to be a combinatio  of the amino acid 
threonine and the sugar sucrose. 
• This formulation maintained nearly complete measles vaccine activity after 6 
months of storage at 4oC or 25oC. 
• Activity loss was greater after storage at 45oC. The virus maintained at least 10% 
of its initial activity until the 12 week time point. After 6 months the activity level 
was detected to be <1% of a control sample. 
 
8.3 Measles Vaccination of Non-human Primates using a Microneedle Patch 
 
 This study examined the delivery of measles vaccine using a dissolving 
microneedle patch using a non-human primate model. Dissolving microneedles were 
created that encapsulated active measles vaccine. These needles were strong enough to 
penetrate the skin and rapidly dissolved after insertion. Furthermore these needles 
retained infectivity following creation and storage at elevated temperatures. Following 
administration into the skin of a rhesus macaque, dissolving microneedles produced 
equivalent antibody titers to the same dose of vaccine delivered using a subcutaneous 
injection. The important findings of this study are summarized below: 
• Dissolving microneedles made from poly-vinyl alcohol were created which 
encapsulated the live-attenuated measles vaccine. 
• These patches were strong enough to penetrate pig skin during initial testing. 
Force testing determined the fracture force for each needle to be approximately 
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0.5 Newtons. Following insertion into pig skin, the bulk of the needle completely 
dissolved within 10 minutes. 
• Needles were inserted into the skin of a rhesus macaque and tested for their ability 
to deliver the measles vaccine. Following insertion it was found that >90% of the 
encapsulated vaccine was delivered into the skin. 
• Both the dissolving microneedle patch and subcutaneous injection groups 
produced a potent neutralizing antibody response. The levels between the two 
groups were found to be statistically equivalent. 
• All animals demonstrated a positive serum measles-sp cific IgM response as 
measured by ELISA 14 days after vaccination. This is considered an important 
marker of a successful measles vaccination. 
• All animals demonstrated increased measles-specific serum IgG titers as 
measured by ELISA following vaccination. The levels between the two groups 
were not statistically different. 
• Following a boost of monovalent measles vaccine delivered subcutaneously, all 
animals demonstrated a measurable increase in antibody titer. 
• Microneedle patches containing measles vaccine proved to be stable after 
extended storage. The patches demonstrated no activity loss after 2 months of 
storage at 4oC or 25oC. 
• Lower activity was seen after storage at 40oC. These patches showed a 1.0 





8.4 Inactivated Polio Vaccination using a Dissolving Microneedle Patch in the 
Rhesus Macaque 
 
 This study focused on development of a dissolving microneedle patch containing 
a full human dose of the trivalent inactivated polio vaccine. Microneedle patches, created 
out of fish gelatin, were used to deliver IPV into rhesus macaques and the response to 
skin delivery was compared to the same dose deliverd using a standard intramuscular 
injection. The major findings of this study are summarized below: 
• Initial testing showed that these patches successfully maintained antigenicity after 
creation as measured by a serotype-specific ELISA. 
• Following administration into the skin of a rhesus macaque, a robust neutralizing 
antibody response was seen to IPV serotype 2 but not to serotypes 1 or 3. This 
phenomena was also observed with the same dose of vaccine delivered using an 
intramuscular injection. 
• Following a boost delivered using the same routes, a marked increase in type 1 
and type 2 antibody titers was seen in both groups. An increase in type 3 titers 
was seen after intramuscular injection but not after microneedle delivery. 
• It was determined that the ELISA used to detect IPVtype 3 was not D-antigen 
specific. A new ELISA was developed which was specific for the immunogenic 
D-antigen region of IPV type 3. 
• This new ELISA demonstrated that the microneedle patches only contained 
approximately 30% of the targeted dose of IPV type 3 before insertion. 
• Neutralizing antibody titers for type 1 and type 2 IPV were equivalent between 
immunized groups. Titers to type 3 were significantly lower in the microneedle 
group. This is thought to be a result of the substantially lower dose delivered. 
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CHAPTER 9  FUTURE DIRECTIONS  
 
9.1 Improving the dissolving measles microneedle patch 
 
 The studies performed showed that the measles vaccine ould be encapsulated 
into a dissolving microneedle patch which maintained activity at 4oC and 25oC for 2 
months. The success of these results were tempered by the fact that the patches stored at 
40oC lost nearly 90% of their activity by the same time point. More work can be done to 
further increase measles vaccine stability. Removing measles vaccine from the cold chain 
would require the creation of a much more stable patch. A more complete screen of 
excipients using the developed eGFP-MeV assay could be performed which may result in 
formulations with an even higher level of stabilizing activity. Current WHO standards 
state that measles vaccine must not lose more than 1.0 log(TCID50) after 2 years of 
storage at 4oC. This is also a good target for high temperature stability. If a microneedle 
patch could be created which met this condition at 40oC, it would provide a compelling 
scientific argument to allow for a measles patch to be transported and stored outside of 
the cold chain. Since the temperature fluctuates significantly between night and day, 
patches may not need to maintain activity at this elevated temperatures for an extended 
period of time. Transient temperature stability may be sufficient. 
 Further testing must also be performed on measles microneedle patches before a 
product could be approved. While patches were tested for measles activity after storage, 
they were not tested for insertion ability or immunogenicity. Since the patches rapidly 
dissolved in the presence of moisture in the skin, testing must be performed to ensure that 
the needles don’t lose mechanical strength following storage. Even packaging designed to 
minimize humidity may result in a small amount of water retention in the patch. It is 
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unknown whether this could result in microneedles that are no longer strong enough to 
pierce the skin. Mechanical testing must be performed after extended storage to ensure 
that the microneedle patches remain sharp and retain the ability to easily insert into the 
skin. Immunogenic testing also needs to be performed after storage. While the TCID50 
assay directly measures viral infectivity, this is not sufficient to confirm that patches 
retain the ability to elicit a potent immune response after delivery. Patches should be 
stored for an extended period of time at a range of temperatures and then inserted into 
cotton rats to determine their immunogenicity. Cotton rats would be recommended since 
rhesus macaques would be prohibitively expensive for this type of study. 
 
9.2 Measles + Rubella patch development 
 
 Currently, the measles vaccine is often co-administered with the rubella vaccine 
during mass vaccination campaigns. This is designed to rapidly expand rubella vaccine 
coverage in addition to the standing goal of measles e imination. A microneedle patch 
which could simultaneously deliver both of these antigens would be extremely beneficial 
to these joint goals. Developmental steps for this patch could follow a similar track as the 
experiments in aim 3. Short term stability of a combination patch should be tested in the 
presence of stabilizing excipients. Once confirmed, patches could be tested in the rhesus 
macaque. Preliminary studies carried out during aim3 showed that rubella vaccine is 
infectious in the rhesus macaque and stimulates a potent antibody response. Further 
optimization could then focus on increasing the stabili y of each vaccine component. 
Unfortunately no rapid screening assay yet exists for rubella, so testing would need to be 
done using a traditional infection and staining assay. 
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9.3 Dissolving inactivated polio microneedle patch enhancement 
 
 While the inactivated polio vaccine dissolving microneedle patch was successful 
in inducing a potent immune response to IPV types 1 and 2, the response to type 3 was 
subpar. This was determined to be the result of inaccurate dosing information provided 
by our type 3 ELISA. Since this assay was not specific for the D-antigen region of IPV 
type 3, it did not detect a substantial drop in activity after microneedle casting and 
creation. After development of a more specific assay, it was found that the dose delivered 
using microneedles was only about 30% of the target full human dose. More work must 
be done to determine the cause of this activity loss and eliminate it. Once a patch is 
created which can maintain the short-term antigenicity of all three polio serotypes, 
another rhesus vaccination could be performed. Thiswould hopefully result in a potent 
antibody response to the entire trivalent vaccine. This is a crucial hurdle that must be 
overcome before this product could move into clinical testing. 
 
9.4 Transgenic mouse polio challenge study 
 
 While neutralizing antibody titers can be predictive of protection from wild-virus 
a true challenge study would be very beneficial to any eventual FDA clinical trial 
application. Unfortunately, very few animal models currently exist for this kind of study. 
One that is well-studied and WHO-approved, is the Tg-PVR21 mouse model. This 
consists of a genetically modified mouse that has been altered to express the human 
poliovirus receptor. This animal displays clinical signs of infection after intracranial or 
intramuscular application of a sufficient quantity of wild-type poliovirus. It is currently 
used by the WHO during studies to verify the efficacy of polio vaccine candidates. This 
model could be used to examine the protective ability of IPV delivered using a 
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microneedle patch. Mice would be vaccinated using both dissolving needle patches and a 
traditional intramuscular injection. After approximately 1 month, the animals would be 
challenged using a 10x PD50 dose of wild-type poliovirus. Since each serotype of IPV 
only protects against the companion wild-type strain,  single serotype would need to be 
chosen for testing. IPV type 2 is the mostly widely used in the literature and requires the 
lowest dose to achieve seroconversion. The animals typically display signs of paralysis 
within 10 days of infection, so daily monitoring of activity and weight would be required. 
This could prove as an important preclinical study proving the efficacy of microneedle 








A.1.1. Excipients used in stability screening study. 
 
Table 2: Excipients and concentrations chosen for stability study. 
All excipients were acquired from Sigma-Aldrich, St. Louis, MO. All amino acids 
were in the L-configuration and all sugars were in the D-configuration unless 
indicated otherwise. 
Proteins 
300 mM Alanine 
BioXtra, USP-grade, >98.5% pure 
 
300 mM Arginine 
Reagent-grade, >98% pure 
 
300 mM Asparagine 
Bioreagent, suitable for cell culture, >98% pure 
 
300mM Cysteine 
NI-grade, >97% pure 
 
300 mM Glutamine 
ReagentPlus-grade, >99% pure 
 
300 mM Glycine 
BioUltra-grade, >99% pure 
 
300 mM Histidine 
USP-grade, cell culture tested 
 
300 mM Isoleucine 
Reagent-grade, >98% pure 
 
300 mM Leucine 
USP-grade, >98.5% pure 
 




300 mM Methionine 
Reagent-grade, >98% pure 
 
100 mM Phenylalanine 
Reagent-grade, >98% pure 
 
300 mM Proline 
USP-grade, cell culture tested 
 
300 mM Serine 
USP-grade, >98.5% pure 
 
300 mM Taurine 
>99% pure 
 
300 mM Threonine 
Reagent-grade, >98% pure 
 
300 mM Tyrosine 
Reagent-grade, >98% pure 
 
300 mM Valine 













L-form, microbiology-grade, >99% pure 
 
300 mM Arabitol  















Monohydrate, BioUltra-grade, >99% pure 
 
15% Raffinose 






















Low molecular weight 
 
2%, 4% Human Serum Albumin  
Lyophilized powder, >97% pure 
 
2% Lactaalbumin Hydosylate 
Microbiology-grade, >11% nitrogen impurity 
 
1 M MgCl2 
BioUltra-grade, solution in water 
 
1 M MgSO4 
Molecular biology-grade, solution in water 
 
1% Sodium oxalate 





A.2.1. Neutralizing antibody titers after measles vaccination using metal 
microneedles in the rhesus macaque. 
 
 
Figure 30: Measles plaque neutralization data (metal microneedle). 
Neutralizing titers were obtained from rhesus macaque sera using the 
method described earlier. Samples were tested weekly. This data represents 
the groups which received either a subcutaneous injection or a coated, 
metal microneedle insertion. The arrow indicates the date that a 100% dose 
of monovalent measles vaccine was delivered to all nimals subcutaneously. 
The neutralizing titers between the two groups were not statistically 
different except at days indicated. The asterisk (*, **) represents a 
significant difference (p<0.05 or 0.005) as measured by ANOVA. The data 





A.2.2. Neutralizing antibody titers after IPV delivery using metal microneedles in 
the rhesus macaque. 
 
 
Figure 31: Neutralizing titers to IPV following vaccination (metal microneedle). 
Sera was taken from rhesus macaques weekly following vaccination. Neutralizing 
titers were determined using a serotype-specific plaque micro-neutralization assay. 
The titers for each day were not statistically significant unless otherwise indicated. 
There was no statistical difference in titer for any serotype until after the boost was 
delivered. Each data point represents the average (N = 4) ± SD. The asterisk (*, **, 
***, or ****) rep resents a significant difference (p<0.05, 0.005, 0.0 5 and 0.00005 
respectively) as measured by ANOVA. Seropositivity was defined as a titer greater 
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